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Advancing HIV Prevention  Introduction 
Introduction 
Since the first cases of HIV/AIDS were recognized in 1981, the Centers for Disease 
Control and Prevention (CDC) and its partners have worked to combat the epidemic. Our 
goal has always been to stop transmission and reduce the burden of HIV/AIDS. The new 
initiative, Advancing HIV Prevention: New Strategies for a Changing Epidemic (MMWR 
April 18, 2003; 52:329-356), supports the prevention work of the past two decades and 
expands and strengthens our efforts by modeling new strategies on proven approaches 
that have been used successfully in preventing other infectious diseases.  
  
Stable HIV-associated morbidity and mortality, concerns about possible increases in HIV 
incidence, and the recent availability of a simple, rapid HIV test combined with strong 
prevention collaborations among communities heavily affected by HIV support the need 
to reassess and refocus some of CDC's HIV-prevention activities. An emphasis on greater 
access to testing and on providing prevention and care services for persons living with 
HIV can reduce new infections and lead to reductions in HIV-associated morbidity and 
mortality. In addition, simplifying prenatal and other testing procedures can lead to more 
effective use of resources that CDC provides to prevent perinatal and other HIV 
transmission. 
 
CDC’s HIV prevention activities over the past two decades have focused on helping 
uninfected persons at high-risk for acquiring HIV change and maintain behaviors to keep 
them uninfected.  Despite the success of these efforts in reducing HIV incidence in the 
late 1980’s and early 1990’s, the number of new HIV infections is estimated to have 
remained stable around 40,000 per year since the early 1990’s and the number of persons 
living with HIV continues to increase.  The next decade promises new hope as three 
primary areas of HIV prevention are emphasized: early detection of persons who are HIV 
positive and referral to 
treatment and care 
services, prevention for 
persons living with 
HIV, and prevention for 
persons who are at high 
risk for HIV infection. 
The new initiative 
emphasizes the first t
of these three areas
broadening our 
prevention activities to 
strengthen our fight 




CDC, other federal 
agencies, and the HIV 
prevention community 
will continue their work 
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prevention efforts in these three areas are sustained and re-energized as an integrated 
approach. This broad scope will bring the best prevention science to the fight against 
HIV/AIDS to reduce HIV transmission, including mother-to-child transmission.  
 
Collaboration  
The new initiative will require new partnerships with extensive involvement and 
coordination between CDC, the public health community, and the medical care 
community. With the support of the federal Department of Health and Human Services, 
CDC and its partners, including other federal agencies, state and local health 
departments, community-based organizations, non-governmental providers, and 
professional organizations, will implement this new initiative and energize our efforts to 
meet the challenges of this changing epidemic. 
 
CDC is expanding its collaboration with the Health Resources and Services 
Administration, the American Hospital Association, and private health care providers to 
coordinate the implementation of this initiative. Partners in implementation include Ryan 
White Care funded programs, community health centers, hospitals, and private medical 
plans. CDC is also working with professional medical and nursing organizations, 
including the American Medical Association, the National Medical Association, the 
American College of Obstetrics and Gynecology, the American Nursing Association, the 
HIV Medicine Association of the Infectious Diseases Society of America (IDSA), and 
the Association of Nurses in AIDS Care to solicit their collaboration and support in the 
development of practice recommendations, policy statements, and dissemination of the 
activities of the initiative. 
 
Current Status of HIV/AIDS in the United States 
From 1995 through 1998, the annual number of new AIDS cases declined 38% from 
69,242 to 42,832, and deaths from AIDS declined 63% from 51,670 to 18,823. Since 
1998, the decline has stabilized at approximately 40,000 incident AIDS cases and 16,000 
deaths.  The number of perinatal AIDS cases has declined 89% from 954 in 1992 to 101 
in 2001, however approximately 300 infants are infected through mother-to-child 
transmission each year.  
 
CDC estimates that 850,000 to 950,000 persons in the United States are living with HIV; 
of those, an estimated 25% are unaware of their infection. Evidence suggests that as 
many as two-thirds of the estimated 40,000 new HIV infections each year occur through 
transmission from persons who are unaware of their HIV-positive status. Many persons 
receive the diagnosis late in the course of the disease. As many as 40%-45% of persons 
testing positive for HIV received their first positive test results less than a year before 
AIDS was diagnosed. With an average of 10 years between HIV infection and an AIDS 
diagnosis, this suggests that people are living with HIV for many years before they are 
aware of their infection. 
 
The New Initiative  
This new initiative emphasizes the need for HIV testing and prevention efforts in both 
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learn their status and are successfully referred into treatment and prevention services as 
early as possible.  An important strategy is to incorporate HIV screening into medical 
care services on the same voluntary basis as other medical tests in order to increase the 
number of persons living with HIV who are aware of their infection.  
 
Testing in non-clinical settings is another area of focus because it is more likely to reach 
members of racial and ethnic minorities and persons who are at high risk for HIV. 
Routine testing in correctional facilities, where the prevalence of AIDS among prison 
populations is 5 times higher than that in the general U.S. population, will help to 
increase the number of persons who know their HIV status and who get the services they 
need while in prison and after release.  
 
Partner counseling and referral services (PCRS) can help to ensure early diagnosis and 
linkage to medical, prevention and other services. In studies of HIV PCRS, 8% to 39% of 
partners tested had previously undiagnosed HIV infection. A range of available 
prevention interventions for persons living with HIV offers greater opportunity to meet 
the prevention needs of persons with HIV infection. These interventions range in 
intensity from group level interventions for persons with fewer prevention needs to 
intensive prevention case management for persons with multiple medical and 
psychosocial challenges.  
 
Although significant reductions have been made in perinatal transmission, 6,000 to 7,000 
HIV-infected women gave birth in the United States during 2000, resulting in 280-370 
HIV-infected infants. For about 40% of these perinatal transmissions, health care 
providers were unaware of the mother’s HIV infection before delivery. 
 
CDC is aware that increasing the focus on prevention for HIV positive individuals has the 
potential to be construed as stigmatizing to people with HIV/AIDS. CDC will be 
conducting a national consultation on HIV/AIDS Stigma in 2003 to discuss strategies to 
address this problem and to identify specific actions CDC and its partners can take to 




The primary goal of the new initiative–to reduce HIV transmission–is not new. The four 
strategies identified to help achieve this goal focus directly on reducing barriers to early 
diagnosis; improving referral to state-of-the-art prevention services, medical care, and 
treatment; and ensuring that prevention programs are in place to assist people living with 
HIV. The HIV prevention initiative emphasizes the use of proven public health 
approaches to reduce incidence and the spread of disease. The initiative consists of four 
priority strategies: 
  
Strategy 1: Make voluntary testing a routine part of medical care. 
Strategy 2: Implement new models for diagnosing HIV infections. 
Strategy 3: Prevent new infections by working with persons diagnosed with HIV. 
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Interim Technical Guidance 
As one of the first steps of the new initiative, CDC has drafted this interim technical 
guidance for HIV prevention grantees. This guidance is just that – information to assist in 
your efforts to conduct HIV prevention activities. The information in this document is not 
a dictated set of activities. These are guiding principles, not policies, and we fully expect 
local experts to modify these interventions to meet the needs of the community served. 
 
This guidance outlines 7 activities to assist with the implementation and achievement of 
the strategies listed above. We hope that the guidance will enhance your activity-planning 
efforts and, if appropriate, help spark new ideas and new directions for your current 
prevention activities. The guidance should also help you plan for related training needs. 
The 7 activities described in the guidance are 
• Routinely Recommended HIV Testing as Part of Regular Medical Care Services 
[Strategy 1] 
• Rapid Testing in Non-Clinical Settings [Strategy 2] 
• Routine Voluntary HIV Testing of Inmates in Correctional Facilities [Strategy 2] 
• HIV Partner Counseling and Referral Services [Strategies 2 and 3] 
• Risk Reduction for Persons Living with HIV [Strategy 3] 
• Prevention in Medical Care Settings [Strategy 3] 
• Achieving Universal HIV Testing of Pregnant Women [Strategy 4] 
 
Each section of this document provides detailed background information and current 
knowledge on the topic; objectives; procedures for implementing strategies; how to work 
with partners, including overcoming barriers to implementation; a real-life example 
(vignette) of a current program that uses some or all of the elements in the guidance; and 
requirements for monitoring and evaluating activities. Each section also includes 
references to help you find supportive and more in-depth information on each topic, as 
well as resources for assistance in understanding and implementing programs. CDC is 
also planning demonstration projects to be conducted in 2003-2005. From these projects 
and from our experience implementing the interim guidance, a revised guidance will be 
developed for distribution at a later date.  
 
CDC will provide training and technical assistance to its grantees to ensure that health 
departments and community-based organizations are equipped to provide the most 
effective prevention interventions to persons at highest risk for transmitting or acquiring 
HIV. CDC will provide guidance on implementation of these activities and will continue 
to improve the procedures based on your feedback and data collected over the coming 
year. We look forward to continuing our strong partnerships with state and local agencies 
in the field to implement state-of-the-art prevention interventions in order to reduce the 
number of new HIV infections. 
 
More people than ever before in the course of the epidemic in the United States are living 
with HIV. Advances in treatment have made it possible for HIV-infected persons to live 
longer, healthier lives. CDC sees these persons as essential partners in HIV prevention. 
This new initiative is designed to give persons easier access to testing to learn their HIV 
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risk persons from becoming infected. We see this guidance as a first step in the new 
initiative to build stronger, more effective programs based on proven public health 
strategies. These efforts and those to come will help us realize new successes in our fight 
against this disease and help to build the necessary foundation to effectively target proven 




CDC.  Advancing HIV Prevention:  New strategies for a changing epidemic.  MMWR 
2003;52:329-332.  Available at:  http://www.cdc.gov/mmwr/PDF/wk/mm5215.pdf
 
Advancing HIV Prevention website:  http://www.cdc.gov/hiv/partners/ahp.htm
 
State Policy Profiles developed by the Infectious Disease Society of America (IDSA) for 
the Health Resources and Services Administration (HRSA): 
http://www.hivma.org/HIV/CEN/ToC.htm
 
The U.S. Department of Health and Human Services:  http://www.hhs.gov.htm
 
Health Resources and Services Administration (HRSA):  http://www.hrsa.gov.htm
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In 1987 the Public Health Service recommended that testing for HIV infection be 
conducted when requested by a patient or recommended by a health care provider on the 
basis of behavioral risks or clinical symptoms. Despite the number of persons tested on 
these grounds, many HIV-positive persons have not been diagnosed or have received a 
diagnosis late in the course of their disease: among persons reported with AIDS, 45% 
received their first positive HIV test result less than 1 year before AIDS was diagnosed.1 
Thus, many persons, unaware of their HIV infection, are unable to benefit from 
prevention and care services that can reduce the morbidity and mortality from HIV 
disease.  In addition, they may unwittingly contribute to the continued transmission of 
HIV infection. 
   
Incorporating HIV screening into routine medical care services in facilities with high 
HIV prevalence is a promising complementary strategy for increasing the number of 
HIV-infected individuals who become aware of their infection.2 Until now, testing, 
performing a test because of a person’s clinical symptoms or behavioral risk factors, has 
been the predominant paradigm for diagnosing HIV. Screening, or performing a test for 
all persons in a defined population, is a basic, effective public health tool used to identify 
an unrecognized condition so that treatment can be offered before symptoms develop.3 
HIV screening meets all of the generally accepted principles that apply to screening4:   
• HIV is a serious disease that can be detected before symptoms develop by using a 
screening test that is reliable, inexpensive, acceptable, and non-invasive. 
• Treatment given before symptoms develop, rather than after symptoms develop, is 
more beneficial for reducing morbidity and mortality. 
• Costs in relation to the anticipated benefits are reasonable. 
HIV infection in clinics and facilities where the population served has a high prevalence 
of HIV is comparable to other infectious diseases such as syphilis, tuberculosis, and 
human papillomavirus, for which screening programs have substantially reduced disease 
burden and improved health. In low-prevalence facilities, HIV counseling, testing, and 
referral should continue to be offered to clients based on risk screening.5
 
HIV screening in high prevalence settings makes sense because testing solely on the basis 
of risks fails to identify many HIV-infected persons.6,7,8  Persons with AIDS make 
multiple visits to hospitals, acute care clinics, and managed-care organizations before 
their AIDS diagnosis, but are never tested for HIV.6 Many providers are uncomfortable 
discussing risk behavior with their patients,9 and many persons may be unaware of, or do 
not disclose, their own or their partner’s risk behaviors.10,11 Routine voluntary HIV 
screening presents an opportunity to reduce the stigma related to HIV testing.3,12  Patients 
are not offended when testing is presented as a policy that applies to all patients because 
they do not feel singled out as “at-risk.”3 More patients accept HIV testing when it is 
offered routinely than when it is based upon risk assessments.11, 12
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Patients’ attitudes seem to support routine voluntary HIV screening. Focus groups 
indicate that many patients, especially those who have been tested for other sexually 
transmitted diseases (STDs), assume they have been tested for HIV, whether or not such 
testing was performed. In some communities where HIV infection is common, being 
screened for HIV is perceived as a part of routine care, similar to regular mammograms 
and blood pressure checks.13
 
Since 1993, CDC has recommended offering HIV testing routinely to all patients in acute 
care settings in areas of high HIV prevalence.5,14,15 When HIV testing has been offered 
routinely in high-prevalence, high-volume health care facilities, the proportion of HIV-
positive tests (2% to 7% in hospitals and emergency rooms)15, 16 is similar to or exceeds 
that observed nationally in publicly funded HIV counseling and testing sites (2.0%) and 
STD clinics (1.5%).17
 
Alternative strategies are necessary to help identify the estimated 25% of persons living 
with HIV who have not been diagnosed through existing efforts. Incorporating voluntary 




The purpose of this document is to provide guidance for state and local health 
departments to 
• Identify health care facilities that serve populations in which HIV prevalence is high 
and where routine HIV screening should be instituted 
• Design and promote simplified HIV screening procedures to make routine screening 
feasible in high-volume, high-prevalence health care settings, which may reduce the 
stigma associated with HIV testing  
• Increase the number of persons who undergo HIV screening in medical care facilities, 
the proportion of persons who receive their HIV test results, and the proportion of 
HIV-infected persons who receive care 
 
Procedures 
Steps for health departments 
1. Work with community planning groups to identify health care facilities serving 
populations in which HIV prevalence is high. Several criteria may be used to guide 
selection: 
a) Prevalence data, when available, demonstrating HIV prevalence > 1% among 
patients served by the facility 
b) AIDS diagnosis rate of ≥ 1 per 1,000 discharges from hospitals, and in health 
centers and clinics in the hospital’s referral network 
c) Receipt of funds under Title I or II of the Ryan White Care Act  
d) Comparison data demonstrating that the facility’s patient population is similar to 
that of other medical care facilities where HIV/AIDS prevalence is high (e.g., 
demographics, high STD rates). 
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2. Promote routine HIV screening in the health care facilities through mechanisms such 
as assessments, social marketing, incentives, assistance with reimbursement, or 
availability for consultations and support services. 
3. Collaborate with CDC and national medical and provider organizations to promote 
routine HIV screening in medical facilities serving populations in which HIV 
prevalence is high. 
4. Develop guidelines for HIV screening with simplified procedures for risk screening 
and prevention counseling, when appropriate. Risk screening and prevention 
counseling may not be appropriate or feasible during episodic or acute care visits and 
should not become barriers to HIV testing. Medical visits in which prevention 
counseling is most appropriate are those in which HIV screening and counseling are 
consistent with the context of the health care visit, including 
a) In response to patient request 
b) When the reason for the visit is related to a behavioral or clinical risk, such as 
substance abuse or symptoms of an STD 
c) When other health promotion services are usually offered (e.g., as part of 
comprehensive health assessments, reproductive health care, or family planning) 
 
Collaboration between the health department and the health care facility 
Each health care facility where HIV prevalence is high will need to develop an individual 
plan for implementing routine HIV screening. Health departments should provide 
consultation and assistance to accomplish the following: 
1.  Establish the facility’s policy for routine HIV screening  
2.  Operationalize the plan for routine HIV screening: 
a) Assess patient flow to identify opportunities during the patient visit for 
incorporating routine HIV screening (e.g., after triage, during waiting periods, or 
when vital signs are measured). 
b) Specify which staff will recommend HIV testing (e.g., clinicians, nurses, or both) 
c) Specify which staff will obtain informed consent. During the visit 
i. Patients should be given written, culturally appropriate information about HIV 
infection, testing, and prevention. 
ii. Patients should be told that HIV testing is routine and is recommended for all 
patients. 
iii. Patients should be told that HIV testing is voluntary and that they have the 
right to refuse testing. 
d) Determine the HIV testing process best suited for the facility and the patients. The 
following factors should be considered: 
i. Type of HIV test (serum test, oral fluid, or rapid test). This may be influenced 
by whether phlebotomy is readily available, the likelihood that patients will 
return for results, and the usual duration of patient visits. 
ii. Location where specimens will be collected or testing performed. 
iii. Specific staff members who will collect the specimen and/or perform the test. 
iv. Appropriate communication and documentation of HIV test results. 
v. Training required for facility staff who will be involved. 
vi. Maintenance of confidentiality. 
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3. Promote routine screening to health care providers through informational sessions and 
by providing tools such as revised patient encounter forms. 
4. Promote routine voluntary screening to patients through informational brochures, 
posters, and waiting room videos, among other communication tools. 
5. Promote stepwise integration of routine screening: initially, financial support or 
health department personnel may be needed to initiate the process and demonstrate 
the acceptability, feasibility, and effectiveness of routine screening. CDC is funding 
demonstration projects that will help determine how best to integrate HIV screening 
into routine care.  
6. Establish follow-up procedures for patients who test positive for HIV, including 
counseling consistent with CDC guidelines and appointment or referral procedures 
for prevention and care services.  Recommendations for counseling and successful 
referral are outlined in the Appendix. On-site resources (e.g., through facility social 
workers) should be available for any patient who may require immediate counseling 
or support. 
7.   Establish procedures and responsibilities for reporting HIV cases to the health 
department and for requesting assistance with partner counseling and referral services 
where appropriate.  
8. Establish mechanisms to monitor implementation of routine HIV screening, including 
the collection of information about the number of patients who are seen in the facility, 
are offered HIV testing, are tested, and receive their test results. 
9.   Establish mechanisms for monitoring maintenance of routine HIV screening, 
including tracking the proportion of patients tested per month. 
10. Establish mechanisms to monitor outcomes of this strategy in the facility, including 
the number of newly diagnosed HIV infections, the proportion of patients who 
receive their confirmed HIV-positive test results, and the proportion of newly 
diagnosed patients who enter care and at what stage of disease. 
11. Anticipate a decrease in the proportion of HIV positive tests when a facility 
transitions from risk-based testing to screening.   
 
Working with Partners and Integration into Existing Services 
To integrate HIV screening into routine medical care, health departments must rely on 
medical facilities and community partners. Health departments can facilitate this 
collaboration by 
1. Coordinating activities with programs funded by the Health Resources and Services 
Administration, including Ryan White Planning Councils and other HIV service 
delivery organizations, state primary care associations, community and migrant health 
centers, health care for the homeless, and public housing primary care clinics  
2. Coordinating training efforts with AIDS Education and Training Centers 
3. Developing a strategy for promoting the support of advocacy groups and community 
leaders for routine voluntary HIV screening 
4. Obtaining endorsements from local medical societies, health care facility 
administrators, and managed care organizations 
5. Supporting implementation through allocation of health department HIV counseling 
and testing resources. 
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Programmatic Considerations 
Before establishing routine HIV screening, health departments and medical care facilities 
must consider how to address policy, financial, and resource barriers. 
1. Legal, regulatory, and logistical barriers, such as separate informed consent for HIV 
testing, may challenge the integration of HIV screening into routine medical care in 
some areas. 
2. Individual insurance plans will have different reimbursement policies for HIV tests 
performed under various International Classification of Disease (ICD) and Current 
Procedural Terminology (CPT) codes. Some insured patients may prefer not to 
submit claims for HIV testing. Resources must be identified for patients who do not 
have the financial resources to pay for the HIV test. 
3. Linkages and resources for HIV care need to be in place. HIV care includes 
prevention and treatment services for persons who test HIV-positive and prevention 
services for high-risk persons who test HIV-negative. 
4. Health departments, medical institutions, and other community agencies must 
consider how to allocate the resources necessary to appropriately implement HIV 
screening.   
 
Vignette 
In 2000, health care providers at Grady Memorial Hospital in Atlanta, Georgia, 
recommended voluntary HIV screening for all patients aged 18 to 65 years who were not 
known to be HIV-positive or who had not been tested during the preceding 6 months.15 
Information brochures and posters encouraging HIV testing were used to promote the 
new policy. Patients who accepted HIV testing signed a consent form and were tested 
with either a rapid or a standard enzyme immunoassay (EIA) test. Patients were not 
charged for the tests. Clinicians, counselors, or trained research staff delivered test 
results. A physician’s assistant contacted HIV-positive persons who had not returned for 
their test results. Approximately 20,000 clinic visits occurred during both the study 
period and during the same period in the preceding year when HIV testing had been risk- 
and symptom-based.  During the study period 1,687 more patients were tested during the 
study period, 27 more HIV infections were diagnosed, and 27 more patients were 
informed of their HIV-positive test result. Twice as many HIV-positive patients (26 
versus 13) entered care, and a higher proportion were tested earlier in the course of 
infection (based on CD4 T cell counts of >200 cells/ml). 
 
Monitoring Implementation   
CDC grantees receiving HIV prevention funds will be required to routinely report the 
following indicators to monitor their HIV testing programs in medical care facilities.  
 
CDC’s HIV Prevention Program Performance Indicators*:  
1. Number and percent of newly diagnosed HIV infections in high prevalence 
settings implementing routine HIV screening (B.1) 
2. Percent of newly identified, confirmed HIV-positive test results returned to  
patients tested (B.2) 
Other program measures:  
 11
Advancing HIV Prevention  Routine HIV Testing in Medical Settings 
3. Percent of newly identified HIV-positive patients who enter into care, as 
documented by either a CD4 count or a visit to an HIV-care clinic 
4. Stage of infection at time of diagnosis as indicated by CD4 count or presence of 
AIDS-defining clinical criteria 
5. Summary data on the comparison between the performance indicators collected in 
routine medical care settings to the same performance indicators for all tests 
reported by CDC-funded HIV counseling, testing, and referral sites in the 
jurisdiction 
 
* The CDC Technical Assistance Guidelines for Health Department HIV Prevention 
Program Performance Indicators provides information on setting baseline, target, and 
indicator specification including appropriate data sources, calculations and reporting 
issues. Note: Performance indicators may have been modified to reflect specific 
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Rapid HIV Testing in Non-Clinical Settings    
 
Current Knowledge 
Outreach efforts for HIV prevention activities provide access to hard-to-reach 
populations at high risk for HIV. Numerous jurisdictions offer counseling and testing for 
HIV in non-clinical settings, often through the use of mobile vans. The U.S. Food and 
Drug Administration’s (FDA’s) approval of oral fluid HIV testing in 1994 greatly 
expanded opportunities for offering HIV testing in settings that were not suitable for 
drawing, handling, and storing blood specimens. 
 
Testing programs in non-clinical venues are more likely to reach members of some racial 
and ethnic minorities and persons at increased risk for HIV. Compared with persons 
tested at conventional testing sites, those tested at non-clinical sites were twice as likely 
to report high-risk heterosexual contacts and 3 to 4 times as likely to report injection drug 
use or male-to-male sex.1 A California outreach program called Neighborhood 
Interventions Geared to High-risk Testing (NIGHT) offers street outreach, HIV 
counseling and testing, and referrals through the use of mobile vans. NIGHT was the 
source of more than 104,000 tests during 1997 and 2001. Compared with other testing 
sources, NIGHT reached a higher proportion of African Americans (28% versus 13%), 
injection drug users (23% versus 11%), stimulant drug users (45% versus 25%), and 
commercial sex workers (12% versus 5%).2
 
The rate of HIV-positive tests in non-clinical settings is generally high and consistently 
higher than at conventional testing sites.1 In Wisconsin, persons tested in outreach were 
23% more likely to test HIV-positive than those tested in clinics.3 Of the 597 persons 
tested in mobile vans and street outreach in a 1999 initiative to enhance prevention efforts 
in African American and Latino communities in 4 U.S. cities, 8.7% were HIV-positive.4 
In South Carolina, 54% of men approached in a gay bar agreed to oral fluid testing; 
although 78% had been tested before, 6% were newly diagnosed with HIV.5 In CDC’s 
Young Men’s Survey in 7 cities, a total of 3,592 15-to-22-year-old men who have sex 
with men approached in 194 non-clinical testing settings (public venues) consented to 
HIV testing. Overall prevalence was 7.2%. Although 79% of the men had been tested 
previously, 203 (82%) of the 249 HIV-positive men did not know that they were 
currently HIV-positive.6
 
Unfortunately, many persons tested in non-clinical settings do not return for their test 
results. CDC’s national data from 2000 indicate that results from nearly half of the HIV-
positive tests performed in non-clinical settings were never received. In California’s 
NIGHT program, mobile testing clients were three times less likely to receive their test 
results than clients tested at conventional sites. In contrast, limited experience to date 
with rapid testing in outreach programs is encouraging. In a Minnesota program, an 
outreach worker regularly visited community-based organizations (CBOs), homeless 
shelters, chemical dependency programs, and needle exchange programs to offer rapid 
HIV testing. When results were provided the same day, 99.9% of those tested received 
their HIV test results. 7  
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Interviews of persons at non-clinical settings reveal features important to the success of 
this type of testing. For high-risk persons at a needle exchange program and gay bath 
houses, 36% of those who had never been tested and 28% of those who had delayed 
testing gave “not wanting to go to a clinic” as their reason.8 Participants in other testing 
initiatives cite a desire to receive HIV results immediately and a need for testing during 
expanded hours as important reasons to increase alternative testing opportunities. 9  
 
The recent FDA approval of the OraQuick Rapid HIV-1 Antibody Test, which can be 
suitable for use in selected non-clinical settings and can provide results in 20 minutes, 
offers an opportunity to take advantage of the benefits of outreach testing and ensure that 
tested persons receive their results. 
 
Objectives 
The purpose of this document is to provide guidance for state and local health 
departments* and collaborating CBOs to 
• Select appropriate non-clinical settings where persons at risk for HIV infection can 
receive rapid HIV testing 
• Build capacity in organizations serving high-risk populations in these settings to 
conduct HIV counseling, testing, and referral using rapid HIV tests 
• Implement rapid HIV testing programs in these settings among populations at high 
risk to identify persons whose HIV infection has not been diagnosed 
 
*Although the testing sites will be in CBOs or other non-clinical venues, the linkages and 
medical technology transfer to implement these programs will require facilitation by 
health departments or other medical and laboratory partners. Thus, the information 
presented here focuses both on health departments and non-clinical providers. 
 
Procedures 
Steps for health departments 
1. Collaborate with community planning groups, community-based service-providers, 
and representatives of populations at high risk for HIV to develop an epidemiologic 
profile of populations in their communities in which HIV infection is likely to be 
under-diagnosed because people (a) do not recognize they are at risk for HIV 
infection and/or (b) do not use traditional HIV counseling, testing, and referral 
services. 
2. Seek input to identify venues where high-risk persons who are likely to benefit from 
intervention programs are known to spend time and where rapid HIV testing could be 
provided without appointments, with little waiting time, and with no barriers such as 
transportation. In communities where the HIV Testing Survey (HITS) has been 
conducted, those data may be helpful in selecting appropriate venues (See 
Attachment). 
3. Solicit suggestions from community groups and members of high-risk populations 
about organizations that have demonstrated access to and established trust among 
these populations. Health departments should identify CBOs and other non-clinical 
settings where these populations can receive HIV rapid testing, counseling, and 
referral.  
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4. Establish partnerships with other organizations that have contact with high-risk 
populations. An incremental approach will be important, beginning with a small 
group of identified organizations in a limited number of non-clinical venues to work 
on the initial development and implementation process (steps 5 and 6). Then, using an 
iterative process, successful programs can continue while lessons learned from 
successful and unsuccessful programs can improve procedures that will be used in 
initiating additional groups of programs. 
5. Hold meetings with the first (or next) group of potential partner organizations to 
explain the need for rapid HIV testing in non-clinical settings and gain their support 
and suggestions on how to implement this activity.  
6. Implement and evaluate testing programs, a few sites at a time, to learn what works, 
what is needed to support a successful program, and what other types of venues 
would support testing. As lessons are learned, begin a new wave of counseling and 
testing programs in non-clinical settings (step 4). 
 
Steps for CBOs 
1. Determine the feasibility of implementing rapid HIV testing by assessing the 
following: does the setting have acceptable lighting, temperature control, and private 
space for providing test results? Is a suitable location that is convenient to the venue 
available (e.g., if offering testing to clients of a needle exchange program)? Do 
members of the priority population remain at the venue long enough to receive 
counseling, testing, and results?  
2. Establish a written agreement between the CBO and the health department and/or a 
laboratory to ensure compliance with the Clinical Laboratory Improvement 
Amendments (CLIA) and state and local regulations and policies. A clear supervisory 
structure should be delineated to ensure responsibility for training and guidance, 
oversight for testing procedures, and coordination. 
3. Establish linkages with a laboratory for confirmatory testing of preliminary positive 
rapid test specimens. This relationship should be formalized with appropriate 
documentation.  
4. Arrange linkages between organizations at different testing venues and appropriate 
medical and social referrals (e.g., housing, Medicaid, partner counseling and referral 
services) for comprehensive follow-up care of persons who have HIV infection. 
5. Establish procedures and responsibilities for reporting HIV cases to the health 
department. 
6. Collaborate with CDC to develop, implement, and monitor training programs to train 
non-clinical providers to perform rapid HIV testing. Essential training elements 
include how to 
a) Perform the test, including procedures performed before, during, and after testing 
b) Integrate testing into the overall counseling and testing program 
c) Develop and implement a quality assurance (QA) program 
d) Collect and transport specimens for confirmatory testing  
e) Document and deliver confirmatory testing results to persons whose rapid test 
results had been preliminary positive  
f) Comply with universal and biohazard safety precautions 
g) Ensure confidentiality and data security 
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h) Ensure compliance with relevant state or local regulations 
7. Evaluate readiness to perform rapid HIV testing. 
8. Establish a system to document consent for testing and test results, and to track 
specimens sent for confirmatory testing.  A central record keeping system could be 
established for multiple testing sites working under the umbrella of one health 
department or CBO. 
9. Obtain detailed locating information on clients whose test results are preliminary 
positive so that they can be contacted and encouraged to come in for care if they fail 
to return for their follow-up appointment. The health department and the testing 
program should specify who is responsible for follow-up if clients fail to return for 
confirmatory test results. 
10. Assemble the testing supplies for easy storage and transportation to each testing site. 
Individually packaged rapid test kits include all the supplies and materials necessary 
to facilitate single client testing in non-clinical settings.  
11. Provide routine QA monitoring at non-clinical testing sites, especially the appropriate 
handling of infectious waste, compliance with the regulations of the Occupational 
Safety and Health Administration, and an exposure control plan for potential 
occupational exposures. 
 
Working with Partners and Integration into Existing Services 
1. Providing HIV testing in non-clinical settings such as bars, bathhouses, and needle 
exchange programs may pose risks to staff safety. Safety training should be included 
in the development of testing programs, and appropriate precautions (e.g., working in 
teams) should be specified. Agreements with law enforcement, owners of social 
venues such as bathhouses or sex clubs, neighborhood associations, and other key 
partners should be established before testing activities begin. 
2. Clients offered HIV testing at non-clinical venues may be under the influence of 
alcohol or drugs or have chronic mental health conditions, any of which may interfere 
with their ability to provide informed consent for voluntary HIV testing, or to 
understand test results. The CBO and the health department should work with 
community mental health providers to establish guidelines and define sobriety 
standards for counselors to use to determine when clients are not competent to 
provide consent. These guidelines should be unambiguous and easy to implement. 
3. After preliminary positive rapid test results have been provided, follow-up procedures 
should be in place to facilitate entry to care. For example, consideration should be 
given to scheduling a specific appointment at the referral medical center where 
confirmatory test results will be provided. HIV counselors from the non-clinical site 
may accompany clients to the medical center to provide support and ensure continuity 
of care.  
4. After confirmed HIV-positive results have been delivered, it may be appropriate for 
counselors who have established good relationships with their clients to begin 
eliciting information about partners or to link clients to the partner, counseling, and 
referral services of their health department partner. 
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Programmatic Considerations 
1. Legal and regulatory barriers, such as state prohibitions, health department policies, 
or state laboratory regulations against giving preliminary HIV test results may 
challenge the implementation of rapid HIV testing in non-clinical settings. 
Consideration should be given, where appropriate, to eliminating such barriers. 
2. To provide accountability and continuity in collaborations, a key contact should be 
identified at the health department and at each testing site and community-based 
program conducting rapid HIV testing. 
3. Linkages and resources for HIV care that are population specific must be identified 
and made available to non-clinical personnel who are providing HIV test results. 
These resources include treatment, prevention, and social services for persons who 
test HIV-positive and prevention services for high-risk persons who test HIV-
negative. 
4. For all HIV testing, specific written policies and procedures for ensuring 
confidentiality must be in place. 
 
Vignette 
In 2002, an HIV testing program using OraQuick HIV-1 test kits was implemented in 
Minneapolis, Minnesota. By working with various CBOs, the program was able to focus 
on specific geographic areas, ethnic groups, and persons who engaged in high-risk 
behaviors (e.g., injection drug users) and who had been identified as priority populations 
within the community. Before conducting testing at a given CBO, the testing team did an 
initial planning visit. They met with the staff and learned about their program. Asking: 
How can HIV counseling and testing best fit into their schedule? Are there times when 
they are already talking about HIV prevention, so that HIV testing might be more readily 
accepted? At this planning visit the CBO staff members learned about the testing 
program, including information about the OraQuick test, patterns of client referral, and 
the need for client confidentiality.  
 
Also at this visit, the team evaluated the physical space of the facility. Most CBOs had an 
adequate meeting area that could be used as a pretest counseling room for groups. 
Finding rooms for individual testing and posttest counseling posed a greater challenge. 
The team asked about time constraints. What will the clients do while they are waiting to 
be tested and waiting for test results?  
 
The CBOs determined how much client education was necessary. Some programs had a 
very structured HIV prevention class, where testing was planned immediately after the 
HIV prevention session. Other CBOs, such as homeless shelters, typically did not have 
structured health talks, so the HIV information provided had to be more complete.  
 
After group pretest counseling, the team members adjourned to the space for individual 
testing. They enlisted a CBO staff member to direct and maintain a steady, efficient flow 
of clients through the process. They performed the OraQuick testing procedure as 
described in the package insert, using what is called the one-worker approach. After 
setting up the necessary supplies, the worker performed the test with Client A, set timer 
A for 20 minutes, and recorded the start time for Client A’s test. Client B came in as 
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Client A left. The worker then set out the supplies for the next test and followed the same 
procedure as before. Just as Client B was leaving, the timer went off for Client A. The 
worker read and recorded the test results and then conducted posttest counseling with 
Client A. An advantage of the one-worker approach is that one person can be efficient. 
The continuity for the client is good because the same worker does pretest counseling, 
testing, and posttest counseling. A disadvantage of this approach is that workers can get 
“assembly line fatigue,” and special procedures may be needed if a test result is positive 
and more complex posttest counseling is necessary. Multitasking skills are needed. At 
large venues, as many as four workers have conducted testing at one time.  
 
Monitoring Implementation  
CDC grantees receiving HIV prevention funds will be required to routinely report the 
following indicators to monitor their HIV testing programs in non-clinical settings.  
 
CDC’s HIV Prevention Program Performance Indicators*:  
1. Number and percent of newly diagnosed HIV infections in non-clinical settings 
(B.1) 
2. Percent of newly identified, confirmed HIV-positive test results returned to  
clients tested in non-clinical settings (B.2) 
3. Percent of facilities reporting a prevalence of HIV-positive tests equal to or 
greater than the jurisdiction’s target set in B.1 (B.3) 
Other program measures: 
4. Percent of newly identified HIV-positive patients who enter care services and 
whose medical records contain documentation such as a CD4 count or a visit to an 
HIV care clinic, if feasible to ascertain 
6. Summary data on the comparison between the performance indicators collected in 
non-clinical settings to the same performance indicators for all tests reported by 
CDC-funded HIV counseling, testing, and referral sites in the jurisdiction 
 
* The CDC Technical Assistance Guidelines for Health Department HIV Prevention 
Program Performance Indicators provides information on setting baseline, target, and 
indicator specification including appropriate data sources, calculations and reporting 
issues. Note: Performance indicators may have been modified to reflect specific 
population or setting characteristics.   
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Attachment 1 – Rapid Testing in Non-Clinical Settings    
 
HIV Testing Survey 
 
Overview 
The HIV Testing Survey (HITS) was funded by CDC in various sites from 1996-2002 
through HIV/AIDS Surveillance cooperative agreement funds.  HITS monitored HIV 
testing patterns by assessing reasons for seeking or avoiding testing, examining 
knowledge of state policies for HIV surveillance, and assessing HIV testing patterns 
among persons at high risk for HIV. In addition, HITS collected behavioral risk 
information from persons at high risk for infection.  
 
HITS was anonymous and cross-sectional and surveyed populations at high risk for HIV 
infection. The core populations included men who have sex with men (MSM), injection 
drug users (IDUs), and heterosexual adults at high risk. Areas had the option of sampling 
a population of local interest. To recruit HITS participants, the study was conducted in 
several cities within a state (generally) at 3 venues: gay bars, street locations in areas of 
heavy drug use, and sexually transmitted disease (STD) clinics. At least 100 persons in 
each population group were interviewed. This number meant that each participating state 
had a minimum sample of 300 persons. Persons who had not been tested or who did not 
report that they had tested HIV-positive were interviewed. Persons who reported they 
were HIV-negative were interviewed as well. 
 
Population 
Regardless of the venue, persons who were at least 18 years of age, who were able to 
give informed consent, and had resided in the state for at least 1 year were eligible for an 
interview. In addition, the following behavioral criteria applied for each risk group: men 
at MSM venues (e.g., gay bars) if they had had sex with a man within the past 12 months; 
IDUs if they had injected drugs within the past 12 months; and heterosexual adults at 
high risk who had come to an STD clinic because of a suspected STD, had not been 
treated during the past 90 days, were not at the clinic because of referral or follow-up, 
and had not had homosexual sex within the past 12 months. 
 
Location of HITS and year(s) of survey 
HITS–1 (1996): Arizona, Colorado, Maryland, Missouri, Mississippi, New Mexico, 
North Carolina, Oregon, Texas. HITS–II (1998): Arizona, Colorado, Missouri, 
Mississippi, New Mexico, Oregon, Texas. HITS–2000: Florida, Illinois, Kansas, Nevada, 
New York, Texas, Washington, and New York City. HITS–2001: California, Louisiana, 
Vermont, and Philadelphia. HITS–2002: Florida, Illinois, Michigan, New Jersey, 
Washington, and Houston, Los Angeles County, New York City, and Philadelphia. 
Asian/Pacific Islander HITS (2002): Seattle/King County, Washington. Migrant Farm 
Worker HITS (2002): California. Native American HITS: Portland, Oregon (2001, 2002), 
and Houston (2002). Transgender HITS (2002): San Francisco.  
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Contact Person(s) 
State or local health department, HIV/AIDS surveillance coordinator or HITS site 
coordinator.  CDC, Division of HIV/AIDS Prevention, Behavioral and Clinical 
Surveillance Branch. 
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Routine HIV Testing of Inmates in Correctional Facilities 
 
Current Knowledge  
In the United States, approximately 2 million people are currently incarcerated.1 An 
additional 4 million individuals are on parole or probation.2 Men represent the 
overwhelming majority of the incarcerated population (92%); however, the proportion of 
women has been steadily increasing in recent years.2 Minority populations are 
disproportionately represented among people incarcerated, with recent estimates 
indicating that 12% of African-American males and 4% of Hispanic males in their 
twenties and early thirties are incarcerated.2   
 
Prisons generally house individuals with sentences of 1 year or longer,3 and there are 
currently 1.3 million inmates housed in state and federal prisons.1 Jails currently house 
roughly 600,000 inmates.2 Jails are operated by a city or county and house people 
awaiting hearings, trials, transfer to prison, or misdemeanor convictions. People detained 
in jails usually serve less than 1 year.  The majority serve less than two weeks.3  Most 
inmates are eventually released, but many are re-incarcerated within six months..4 This 
results in 7.5 million people released annually.5 
 
Many individuals entering correctional facilities have a history of high-risk sexual 
behaviors, substance abuse, or both. As a result, high rates of HIV and sexually 
transmitted diseases (STDs) have been documented among persons entering the 
correctional system.5 In 1999, there were more than 25,000 (2.0%) federal and state 
prison inmates, and more than 8,600 jail inmates (1.7%) known to be HIV-positive.6 In 
addition, the prevalence of AIDS among prison populations is 5 times higher than that in 
the general U.S. population (0.60% versus 0.12%).6 Recent estimates suggest that nearly 
25% of people living with HIV pass through the correctional system.7 Currently, less than 
half of the prison systems and few jails routinely provide HIV testing on entry.8 
Therefore, many individuals who may be infected are not routinely offered HIV testing. 
Correctional systems should routinely offer HIV testing as a component of the standard 
medical intake evaluation for all inmates. Routine HIV testing could either be in the form 
of standard enzyme immunoassay (EIA) and Western Blot testing or rapid HIV testing 
with appropriate confirmation testing. Health departments should initiate partner 
counseling and referral services (PCRS) for contacts of these HIV infected persons. 
 
Persons incarcerated for less than 30 days may not receive traditional HIV counseling 
and testing (C&T), and, if they do, they are likely to be released before their test results 
are available. Use of rapid HIV testing could help ensure this population receives their 
test results. The RESPECT 2 study showed that HIV C&T that used a rapid HIV-
screening test was as effective as traditional HIV C&T.9 Therefore, routinely providing 
rapid HIV C&T services for this population can greatly increase the proportion of 
persons tested and notified of their test results prior to release. Persons infected with HIV 
and persons at high risk for infection should be identified and referred to care, treatment, 
and prevention services in the correctional facility. For infected persons being released, 
referral and linkage to these services in the community is essential.  
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Objectives 
The purpose of this document is to provide guidance to state and local health departments 
and correctional facilities to achieve 
• Routine HIV testing during intake medical evaluation to identify new infections 
among inmates whose HIV status is unknown or has been negative on previous tests 
• Routine HIV testing during intake medical evaluation to confirm HIV positivity for 
inmates who report that they are infected 
• Confidential notification to all tested inmates of their HIV test results 
• Referral of HIV-infected persons to appropriate antiretroviral care, treatment, and 
prevention services. If available, referrals should be made to programs and services in 
the correctional facility, the community, or both 
• Referral of persons at high-risk of acquiring HIV to prevention services. Referrals 
include linkages to available programs and services both in the correctional facility 
and the community 
 
Procedures  
Steps for health departments  
1. Work with state and local justice and corrections departments to develop policies and 
procedures for routinely offering HIV testing to all inmates during intake medical 
evaluation. Testing procedures should include standard EIA followed by Western 
Blot testing, rapid HIV testing, or both. The inmates projected length of incarceration 
should determine whether an EIA test or a rapid test is offered to the inmate. 
2. Provide training to personnel from the correctional facility, the health department, or 
community-based organizations (CBOs) working in correctional facilities on the 
following:  
a) Confidentiality and data security issues related to HIV testing 
b) Routinely offering HIV testing, including rapid HIV testing, as part of the medical 
evaluation at intake 
c) Documenting test results and refusals of testing 
d) Understanding the meaning of test results, especially those from rapid HIV testing 
e) Providing inmates confidential notification of their HIV test results 
f) Conducting confirmatory HIV testing for inmates with a positive rapid test result 
g) Identifying care, treatment, and referral services in the correctional facility and 
the community for inmates who test positive for HIV 
h) Referring all persons with a positive test result and persons at high-risk for 
infection to care, treatment or prevention services 
i) Conducting partner, counseling, and referral services  
3. Distribute to correctional facilities in their jurisdiction, an inmate information sheet 
on HIV testing and forms for documenting HIV test results or refusals to test.  
 
Steps for correctional facilities  
1. Provide HIV information sheets to all inmates arriving at the facility. 
2. Routinely offer HIV testing to all inmates during the medical evaluation at intake into 
the correctional facility 
3. Routinely offer prevention counseling in accordance with the CDC counseling, 
testing, and referral guidelines 
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4. Routinely provide confidential notification of HIV test results to all inmates tested 
5. Establish a system to document consent for testing and test results, and to track 
specimens sent for confirmatory testing. 
6. Notify all inmates whose rapid HIV test result is positive that the result indicates a 
preliminary positive result and that a confirmatory test needs to be performed. A 
blood specimen should be obtained from the inmate and confirmatory testing 
initiated. 
7. Establish procedures and responsibilities for reporting HIV cases to the health 
department and requesting assistance with partner counseling and referral services 
8. Each correctional facility must specify written policies and procedures to 
a) Determine eligibility for EIA HIV testing and rapid HIV testing.  In general, 
inmates who are likely to be released before results from EIA testing are available 
should be offered rapid testing during their medical evaluation. 
b) Ensure care and treatment is provided, based on the inmate’s projected length of 
incarceration.  
c) Ensure confidentiality and security of data related to HIV testing. 
9. Initiate the referral process for all HIV-infected inmates and those at high risk of 
acquiring HIV infection by making the first appointment with an appropriate care 
provider, CBO, or both. Whenever possible, the initial appointment should occur 
while the inmate is in the correctional facility. If this is not possible, health 
department or CBO personnel should obtain contact information from the correctional 
personnel, initiate contact with the individual, and accompany the released inmate to 
appointments, if appropriate.   
10. Work with participating CBOs to establish procedures and responsibilities for referral 
services for inmates as part of release planning.  
 
Programmatic Considerations 
Health departments should initiate discussions with correctional systems that do not 
routinely offer HIV testing to inmates during the intake medical evaluation to determine 
their willingness to implement routine HIV testing. Before establishing routine, HIV 
testing, health departments, correctional facilities, and CBOs must consider how to 
address relevant policy, financial, and resource barriers. 
1. In circumstances where rapid testing is used in HIV screening in correctional 
facilities, legal and regulatory barriers, such as state prohibitions or health department 
policies on giving preliminary results, may challenge implementation. Consideration 
should be given to revising these prohibitions, where appropriate.   
2. Linkages and resources for HIV care need to be in place for persons detained in the 
correctional facility and those released to the community.  
3. A key contact should be identified at the health department and at each correctional 
facility and CBO to provide accountability and continuity in the collaboration.  
 
Working with Partners and Integration into Existing Services 
1. Collaboration between the health department, correctional facility, and CBO 
personnel is critical to the successful training and implementation of routine HIV 
screening and prevention services in correctional facilities and in the community. If 
facilities conclude that rapid testing is to be a part of routine screening in the 
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correctional institution, specific training in rapid HIV testing must occur and 
collaboration with a laboratory must be in place. 
2. Partnerships should be developed among health departments, correctional facilities, 
and CBOs so that individuals can be linked to care, treatment, and prevention services 
in correctional facilities and in the community. These relationships should be 
negotiated and formally documented in writing, e.g., a letter of cooperation, 
memoranda of agreement or understanding. 
3. Additional partners with whom to collaborate may include state, county, and local 
police and sheriff departments. 
 
Vignette  
Individuals admitted to the Adult Correctional Institute in Rhode Island through intake 
undergo a medical evaluation.10  During this evaluation, inmates give a brief medical 
history, receive a brief physical examination, and undergo mandatory serum syphilis 
testing. Medical personnel answer questions related to HIV testing and encourage all 
inmates to routinely accept HIV testing during the intake process.  Testing is not based on 
risk perception and is offered in a manner in which inmates have the opportunity to 
refuse HIV testing.  Inmates are provided a standard written consent form before HIV 
testing.  Although counseling before the test is not routinely provided at intake, over 90% 
of inmates are routinely tested for HIV. Test results are provided in a one on one session, 
by an HIV trained counselor. Through a demonstration project, Project Bridge,11 HIV-
positive inmates are provided assistance with accessing medical and social services in the 
community. Enrollment occurs one to three months before release, and plans are made to 
obtain concrete services after release. Support is provided for 18 months after release.  
All health care information, including HIV test results, is kept secure at the medical clinic 
in the correctional facility.  All participants sign consent and release forms granting 
permission to be participant in Project Bridge.   
  
Monitoring Implementation 
CDC grantees receiving HIV prevention funds will be required to routinely report the 
following indicators to monitor their HIV testing programs in correctional facilities.  
 
CDC’s HIV Prevention Program Performance Indicators*:  
1. Number and percent of newly diagnosed HIV infections in correctional facilities 
(B.1) 
2. Number and percent of newly identified, confirmed HIV-positive test results 
returned to inmates (B.2) 
Other program measures:  
3. Number of persons with HIV who are referred for services during incarceration 
4. Number of persons with HIV who use the services to which they are referred 
while incarcerated 
5. Number of persons at high risk for acquiring HIV who are referred for services 
during incarceration 
6. Number of persons at high risk for HIV who use the services to which they are 
referred while incarcerated 
7. Number of persons who are retested for HIV due to reincarceration 
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8. Collection of HIV transmission risk data in accordance with CTR Guidelines 
 
* The CDC Technical Assistance Guidelines for Health Department HIV Prevention 
Program Performance Indicators provides information on setting baseline, target, and 
indicator specification including appropriate data sources, calculations and reporting 
issues. Note: Performance indicators may have been modified to reflect specific 
population or setting characteristics.  
 
References 
1. Harrison P, Beck A. Prisoners in 2001. Bureau of Justice statistics bulletin, U.S. Dept 
of Justice, Office of Justice Programs. 2002;1-16. 
2. Beck A, Karberg J, Harrison P. Prison and jail inmates at midyear 2001. Bureau of 
Justice statistics bulletin. Washington D.C.: U.S. Department of Justice, Office of 
Justice Programs. 2002;1-16. 
3. Polonsky S, Kerr S, Harris B, Gaiter J, Fichtner RR, Kennedy MG. HIV prevention in 
prisons and jails: Obstacles and opportunities. Public Health Reports. 
1994;109(5):615-625. 
4. Petersilia J. When prisoners return to the community: Political, economic, and social 
consequences. Sentencing & Corrections. Issues for the 21st Century. U.S. 
Department of Justice, Office of Justice Programs, National Institute of Justice. 
2000;No. 9. 
5. Hammett TM, Harmon P, Rhodes W. The burden of infectious disease among 
inmates of and releasees from U.S. correctional facilities, 1997. Am J Public Health. 
2002;92(11):1789-1794. 
6. Maruschak L. HIV in prisons and jails, 1999. Bureau of Justice Statistics Bulletin, 
Office of Justice Programs, U.S. Department of Justice. 2001;1-11. 
7. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human 
immunodeficiency virus in correctional facilities: A review. Clinical Infectious 
Diseases. 2002;35:305-312. 
8. Hammett TM, Harmon P, Maruschak LM. 1996-1997 update: HIV/AIDS, STDs, and 
TB in correctional facilities. Washington, D.C.: U.S. Department of Justice, National 
Institute of Justice. July 1999. 
9. Metcalf CA, Cross H, Dillon BA, et al. Randomized controlled trial of HIV 
counseling with rapid and standard HIV tests (RESPECT-2). XIV International AIDS 
Conference: Barcelona, Spain. July 7-12, 2002. 
10. Desai AA, Latta TE, Spaulding A, Rich JD, Flanigan TP. The importance of routine 
HIV testing in the incarcerated population: The Rhode Island experience. AIDS 
Education and Prevention. 2002;14(Supplement B):45-52. 
11. Rich JD, Holmes L, Salas C, et al. Successful linkage of medical care and community 
services for HIV-positive offenders being released from prison. Journal of Urban 







Advancing HIV Prevention  Routine HIV Testing of Correctional Facility Inmates  
Resources 
 
AIDS Education and Training Centers: http://hab.hrsa.gov/educating.htm
 
Bureau of Justice Statistics: http://www.ojp.usdoj.gov/bjs/
 
CDC. Revised Guidelines for HIV Counseling, Testing, and Referral. 
http://www.cdc.gov/mmwr/PDF/rr/rr5019.pdf
 
National Commission on Correctional Health Care: http://www.ncchc.org
 
Public Health and Corrections Collaboration: http://www.ncjrs.org/pdffiles/169590.pdf
 
Rapid testing: http://www.cdc.gov/hiv/rapid_testing/  
 
CDC. Technical Assistance Guidelines for CDC’s HIV Prevention Program Performance 
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HIV Partner Counseling and Referral Services  
 
Current Knowledge 
Evidence suggests that most new HIV infections originate from HIV-infected persons not 
yet aware of their infection.1 This emphasizes the need to identify HIV-infected persons 
and link them to medical, prevention and other services as soon as possible after they 
become infected. One strategy for accomplishing this is voluntary partner counseling and 
referral services (PCRS), including partner notification (PN).2,3,4 
 
PCRS assists HIV-infected persons with notifying their partners of their exposure to HIV. 
Notified partners, who may not have suspected their risk, can then choose whether to be 
tested for HIV, enabling those who test HIV positive to receive early medical evaluation, 
treatment, and prevention services, including risk-reduction counseling. A key element of 
PCRS is informing current and past partners that a person who is HIV-infected has 
identified them as a sex or injection-drug-paraphernalia-sharing partner and advising 
them to have HIV counseling and testing. Among sex partners, close partners and those 
with whom contact has been recent, frequent, or of longer duration are more likely to be 
notified5,6,7,8; however, PCRS should include casual partners (or contacts), as well. 
Informing partners of their exposure to HIV is confidential, in that partners are not told 
who reported their name or when the reported exposure occurred, nor is information 
about the partners reported back to the original HIV-infected person. It is voluntary in 
that the infected person decides which names to reveal to the interviewer. 
 
PCRS can be an effective tool for reaching persons at very high risk for HIV infection: in 
studies of HIV PCRS, 8%-39 % of partners tested were found to have previously 
undiagnosed HIV infection.9 However, a recent survey of health department staff in U.S. 
areas with high reported rates of HIV found that, in areas with mandatory HIV reporting, 
only 52% of persons infected with HIV were interviewed for PCRS.10 PCRS has been 
found to be cost-effective.11,12,13 Acceptability of PCRS has been indicated in surveys of 
individuals seeking HIV testing, HIV-infected persons, and notified partners, in which 
the majority of respondents have indicated support for PN.14,15,16
 
HIV PCRS includes several elements: identifying, locating, and interviewing HIV-
infected persons (index patients) to offer PCRS and elicit names of partners; locating 
partners and notifying them of their exposure to HIV; and providing HIV counseling, 
testing, and referral services to the partners. PCRS is usually done by health departments. 
In some areas, community-based organizations (CBOs) or other agencies perform at least 
some parts of PCRS (e.g., interviewing index patients to elicit partner names); however, 
state or local laws and regulations may limit or prohibit PCRS being done outside the 
health department. 
 
There are 3 main strategies for reaching and informing partners of their exposure. In 
provider referral, the clinical care provider or health department staff, with permission 
from the HIV-infected client, informs the partner and refers him or her to counseling, 
testing, and other support services. Although some clinicians may wish to take on the 
responsibility for informing partners, one observational study suggested that health 
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department specialists were more successful than physicians in interviewing patients and 
locating partners.17 In patient or client referral, the HIV-infected person accepts full 
responsibility for informing his or her partners of their possible exposure to HIV and for 
referring them to HIV counseling and testing services. Although some persons initially 
prefer to inform their partners themselves, many clients often find this more difficult than 
anticipated. Furthermore, notification by health department staff seems to be substantially 
more effective than notification by the infected person.18 In contract referral, the infected 
person has a few days to notify his or her partners. If, by the contract date, the partners 
have not come for counseling and testing, they are contacted by the health department. In 
a variation, dual referral, the HIV-infected client and the provider inform the partner 
together. Some reports of partner violence after notification suggest a need for caution, 
but violence seems to be rare.19,20
 
Many states and some cities or localities have laws and regulations about informing 
partners of their exposure to HIV. Some health departments require that even if a patient 
refuses to report a partner, the clinician must report to the health department any partner 
of whom he or she is aware. Some states also have laws regarding disclosure by 
clinicians to third parties known to be at significant risk for future HIV transmission from 
patients known to be infected. This is called duty to warn.21 The Ryan White CARE 
Reauthorization Act requires that health departments receiving Ryan White funds show 
“good faith” efforts to notify marriage partners of HIV-infected patients.   
 
Objectives  
The purpose of this document is to provide guidance to state and local health departments 
to achieve the following: 
• Routine provision of PCRS, in public and private settings, to persons with newly 
diagnosed HIV 
• Ongoing provision of PCRS to HIV-infected persons who remain sexually active or 
continue to inject drugs 
• Effective linkage of persons diagnosed with HIV through PCRS to medical 
evaluation, treatment, prevention, and other appropriate services 
 
Other agencies and providers doing PCRS must work closely with their respective health 
departments and adhere to all applicable laws and regulations. 
 
Procedures 
Steps for health departments 
1. Develop and implement programs to provide PCRS in public and private sectors to all 
persons newly diagnosed with HIV. These programs should address all steps of 
PCRS, including  
a)  Contacting persons newly diagnosed with HIV to offer them PCRS 
b)  Interviewing persons who accept PCRS to elicit names of and locating 
information for sex and  injection-drug-paraphernalia-sharing partners 
c)  Locating, notifying, counseling, testing, and providing test results to partners 
d) Linking partners, especially those who test positive, to appropriate medical 
evaluation, treatment, prevention, and other services 
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2. Ensure that PCRS is 
a)  Confidential in all aspects 
b)  Available with both confidential and anonymous counseling and testing 
c)  Culturally sensitive and acceptable to the affected population 
d)  Timely (i.e., locating and notifying activities are initiated and completed 
promptly) 
3. Ensure that information about how to access PCRS services is easily accessible by 
health care providers in the public and private sectors, CBOs, and other agencies 
diagnosing or providing services to HIV-infected persons. 
4. Encourage providers, CBOs, and other agencies providing services to HIV-infected 
persons to routinely screen clients for ongoing sexual and injection-drug-use activities 
and to provide PCRS, directly or through referral, for new partners who may have 
been exposed to HIV. 
5. Ensure that providers, CBOs, and other agencies diagnosing or providing services to 
HIV-infected persons are aware of all laws and regulations relevant to PCRS in their 
respective jurisdictions. 
6. Ensure that all clients receiving PCRS are assessed for the possibility of partner 
violence and, when indicated, are referred to agencies with expertise in this area.  
7. Ensure that all staff members doing PCRS receive initial and ongoing training in 
PCRS methods and receive close supervision and routine, periodic performance 
evaluation. Training curricula for PCRS and PN are available from CDC, and many 
courses are available from health departments and the National Network of STD/HIV 
Prevention Training Centers  
8. Work with health care providers, CBOs, and other organizations serving or 
representing HIV-infected persons to educate them about the potential benefits of 
PCRS for HIV-infected persons, their partners, and the community and to develop 
community support for these services. 
9. Work closely with non-health department agencies (e.g., CBOs) that are considering 
providing PCRS services to assist in planning their programs, including identifying 
which elements of PCRS the agency should conduct, how the agency’s PCRS 
activities will be coordinated with health department PCRS activities, how 
appropriate reporting to the health department will be ensured, and what laws and 
regulations may be applicable to the program. 
 
Working with Partners and Integration into Existing Services 
1. PCRS is part of a comprehensive array of services needed by HIV-infected persons 
and their partners. It should be fully integrated with those services, beginning when a 
client first receives HIV counseling and testing and continuing after the client enters 
care and treatment services.  
2. PCRS cannot function as an isolated activity in the health department. Health 
departments should work closely with private sector and other providers (including 
Ryan White Care funded programs) to help them develop strategies for integrating 
PCRS into their services (e.g., routinely screening HIV-positive clients for behavioral 
and clinical risks for HIV transmission to identify those who should be offered 
PCRS). 
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3. Whether HIV PCRS is conducted by HIV/AIDS program staff or by disease 
intervention specialists (DIS) in sexually transmitted disease (STD) programs, where 
PN for other STDs is also conducted, HIV/AIDS and STD programs should 
collaborate to provide the most effective services and to use resources effectively. 
 
Programmatic Considerations 
1. Some PCRS programs focus primarily on patients diagnosed in the public sector, 
especially STD clinics; however, most persons with HIV are diagnosed in the private 
sector. Health departments should work with private sector health care providers 
(including programs funded under the Ryan White Care Act) to help foster 
understanding of and support for providing PCRS to HIV-infected persons diagnosed 
in the private sector. 
2. PCRS may place a substantial burden on health department resources. Managers may 
need to prioritize PCRS activities, such as the order in which HIV-infected persons 
are offered PCRS or the order in which partners are located and offered PCRS.  
3. Concerns often voiced regarding HIV PCRS include potential violations of 
confidentiality, the stigma associated with HIV, and the potential for partner violence 
associated with PCRS. It is critical that all PCRS programs include strict procedures 
for ensuring privacy, confidentiality, and security of data, as well as screening for and 
addressing potential partner violence. 
4. Some states have laws and regulations that limit partner notification activities. 
Amendment of these laws should be considered, where appropriate, in order for 
PCRS to be successfully implemented. 
5. In some instances, HIV-positive clients may have sex or may share injection 
equipment with persons they do not know. In these circumstances, general 
information obtained through PCRS can be used to identify high-risk areas and 
venues where PCRS programs can provide or arrange for outreach services. A more 
recent phenomenon is use of the Internet for finding sex partners; strategies for PCRS 
in this situation need to be explored. 
6. In some circumstances, ensuring confidentiality may be difficult. For example, if an 
HIV-positive client (index patient) has a spouse or other partner who is known to 
have had no other partner, the PCRS provider and index patient should fully discuss 
all available options for notifying the partner and together formulate the most 
appropriate plan. For example, a dual-referral approach, in which the HIV-infected 
client informs the partner of his or her HIV status in the presence of the PCRS 
provider, might be appropriate in this situation. By having a professional counselor 
present, this approach supports the client and may reduce other potential risks. If 
there is any concern about possible partner violence, assistance should be sought from 
persons with expertise in violence prevention. 
7. Unlike bacterial STDs, HIV is not curable; therefore, PCRS should be an ongoing 
process for clients who have new sex or injection-drug-paraphernalia-sharing 
partners. Clients who remain sexually active or continue to use injection drugs should 
be counseled regarding self-disclosure of HIV status and provided opportunities to 
develop their self-disclosure skills. 
8. Many questions remain regarding the best approaches for conducting PCRS (e.g., best 
methods for interviewing and eliciting partner names, optimal length of time period 
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used for interviewing, tailoring elicitation and notification procedures to specific 
populations, potential roles of agencies other than health departments). These 
questions should be addressed through evaluation of existing programs and by 
conducting operational research. 
 
Vignette 
Since 1989, North Carolina has offered HIV PCRS to persons who test positive for HIV. 
PCRS is done by DIS. DIS are specially trained health professionals who attempt to 
locate HIV-infected patients and their exposed partners and ensure that both are referred 
to HIV and syphilis evaluation, treatment, and prevention services. When a positive HIV 
test result is reported to the local health department by a medical care provider or clinical 
laboratory, a DIS is assigned to the investigation. After verifying that the person has not 
been previously reported as HIV positive, the DIS contacts the patient’s medical provider 
to initiate PCRS. The DIS reviews medical records to obtain demographic and clinical 
information about the reported patient (i.e., index patient); attempts to contact the index 
patient; conducts a voluntary, confidential, in-depth interview with the index patient, 
requesting information on all sex and injection-drug-paraphernalia-sharing partners 
within the past year; and assesses the potential for partner violence. The DIS ensures that 
all HIV-infected clients have received HIV prevention counseling, are informed about 
measures for reducing or preventing HIV transmission, and, if needed, receive referrals to 
HIV care and case management. 
 
After obtaining partner information, the DIS searches regional records to determine 
whether named partners have already been reported as HIV infected. The DIS then offers 
index patients the options of provider referral or contract referral to assist in notifying 
partners, not already known to be HIV positive, of their possible exposure to HIV. When 
located, partners are informed that they may have been exposed to HIV and are either 
referred to HIV counseling and testing clinic services or are provided these services on-
site. 
 
In North Carolina in 2001, there were 1,603 newly diagnosed HIV and AIDS cases; 166 
(10%) were diagnosed because of PCRS. Through PCRS, 1,532 sex or needle-sharing 
partners were notified; of those, 404 (26%) had previously tested HIV positive. Of 1,128 
not previously known to be HIV-positive, 610 (64%) were notified, counseled, and tested 
for HIV; 125 (20%) of these were newly diagnosed with HIV infection. Of the 1,532 
partners interviewed, half had not been tested previously; 488 (64%) of these were tested 
through PCRS, and 108 (22%) were found to be positive for HIV. Of 188 partners who 
had previously tested negative, 122 (65%) were retested through PCRS; of those, 17 
(14%) were newly diagnosed with HIV infection. 
 
Monitoring Implementation 
CDC grantees receiving HIV prevention funds will be required to routinely report the 
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CDC’s HIV Prevention Program Performance Indicators*:  
1. Number and percent of contacts with unknown or previously negative HIV 
serostatus receiving an HIV test after PCRS notification (C.1) 
2. Number and percent of contacts with a newly identified, confirmed positive HIV 
test among all contacts tested (C.2) 
3. Number and percent of contacts with a previously known, confirmed positive HIV 
test among all contacts (C.3)  
Other program measures: 
4. Number of persons newly diagnosed and reported with HIV (index patients) 
5. Collection of HIV transmission risk data in accordance with CTR Guidelines 
6. Number of index patients located, offered, and who accepted PCRS 
7. Demographics of index patients and contacts (e.g., race/ethnicity, gender, 
socioeconomic status) 
8. Number of named contacts  
a) For each index patient accepting PCRS 
b) Located, offered, and who accepted PCRS 
c) With a positive test result who are successfully linked to medical evaluation, 
treatment, and prevention services 
 
* The CDC Technical Assistance Guidelines for Health Department HIV Prevention 
Program Performance Indicators provides information on setting baseline, target, and 
indicator specification including appropriate data sources, calculations and reporting 
issues. Note: Performance indicators may have been modified to reflect specific 
population or setting characteristics. 
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Prevention Interventions with Persons Living with HIV 
 
Current Knowledge  
Because of the use of newer and more effective treatments, increasing numbers of 
persons living with HIV in the United States are living longer. CDC estimates that 
850,000 to 950,000 persons in the United States are living with HIV, and that 25% of 
these individuals are unaware of their serostatus.1,2 Although numerous effective 
prevention interventions have concentrated on HIV-negative populations, to date only a 
small number have focused on HIV-positive persons.3-5   
 
Most people who find out that they are HIV-positive reduce their sexual and drug-use 
behaviors5. However, some HIV-positive persons have intermittent or ongoing 
difficulties with changing their behaviors and focusing on HIV prevention. For some 
people, a relatively less intensive intervention (e.g., a support group or structured risk-
reduction, skills-building group) will be sufficient to lead to significant change in 
behavior. Other HIV-positive persons may need more intensive prevention services (e.g., 
a couples or individual-level approach) or may benefit from a combination of prevention 
services.  
 
Often people who require more intensive services are struggling with other psychosocial 
factors (e.g., mental illness, substance abuse, domestic violence, homelessness, and 
economic stressors) that affect their risk behaviors. The presence of psychosocial 
challenges may adversely affect HIV-positive persons, decreasing their ability to obtain 
and adhere to proper medical care or to reduce their HIV risk behaviors. Integrating 
consideration of these issues into prevention programs for HIV-positive persons is 
crucial. Agencies should 1) provide or have access to referrals for a range of services of 
different intensities, including psychosocial services and medical care; and 2) screen 
HIV-positive persons and refer them to the needed level of services.   
 
Initially, it is important that persons who are newly diagnosed with HIV are enrolled into 
medical care. Helping HIV-infected persons enter into medical care so they can receive 
treatment, e.g., combination antiretroviral therapy can help suppress viral loads to very 
low levels and slow disease progression. HIV-infected persons who are receiving medical 
care may also benefit from prophylaxis for opportunistic infections and receive treatment 
for other health problems. Recent data from the Antiretroviral Treatment Access Studies 
(ARTAS) found that newly diagnosed persons or those otherwise not in medical care 
were more likely to get into care if they had a case manager to help them compared to 
those persons who were provided with passive referrals to care.6 In the ARTAS study, the 
case managers helped clients find a provider and then assisted with insurance, 
transportation, childcare, and other issues. This emphasizes the role for Ryan White Case 
Managers (RWCMs), funded by the Health Resources and Services Administration 
(HRSA) through their numerous grantees. These case managers actively link their clients 
with HIV/AIDS primary care and help them to overcome other barriers to supportive 
services. The work of the case managers usually results in more clients actually becoming 
a part of the HIV primary care system. A similar system tested in a statewide program in 
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Minnesota used disease intervention specialists (DIS) to actively and successfully link 
HIV-positive youth, ages 13-22 years, to medical care and other relevant services.7 
 
Agencies helping HIV-positive persons enter into medical care and providing a broad 
range of other services, either directly or through actively linked referrals, could have a 
significant effect on reducing the toll of the HIV epidemic in the United States. Important 
ancillary services for HIV-positive persons may include  
• Behavioral interventions to reduce risk behavior 
• Interventions to improve adherence to complex medication schedules 
• Substance abuse treatment 
• Mental health treatment 
• Domestic violence prevention 
• Benefits counseling   
• Family planning services 
• Housing 
Many of these services may be obtained through referrals from a HRSA-funded RWCM. 
The Ryan White CARE Act is the purchaser of HIV care and services for persons without 
insurance or eligibility for other programs.8 The RWCMs attempt to link HIV-positive 
persons to care and other services through benefits counseling and referrals. While the 
RWCMs are permitted to discuss HIV risk reduction with clients, this is not the focus of 
their work, and they usually are not trained to do risk-reduction counseling.  
 
Agencies that choose to focus on prevention interventions for persons living with HIV 
may be challenged by the newness of prevention activities for this target population and 
the small number of programs that have been evaluated for effectiveness. Several 
programs do exist for HIV-positive persons that range from less intensive, group-based 
interventions, to intensive, individualized interventions. These established interventions 
give agencies a range of prevention options to offer to HIV-positive persons. More than 
10 other interventions are now being tested by researchers. Those found to be effective 
should be available for wider use in the next few years. 
 
While the number of existing, effective interventions is limited, a recent review examined 
the correlates of sexual risk among HIV-positive persons.9  This article provides some 
guidance for agencies developing programs by highlighting what is known to be and not 
to be associated with sexual risk among HIV-positive persons.  In addition, it is likely 
(but not known) that existing interventions for HIV-negative persons could be adapted for 
HIV-positive populations.  Messages in adapted interventions should reflect the needs of 
HIV-positive persons to protect their partners as well as themselves.  
 
This document provides a brief overview of interventions with a range of intensities from 
the less intensive group-level interventions to the most intensive risk-reduction 
intervention for persons with HIV, prevention case management. 
 
Group-Level Interventions for HIV-Positive Persons   
Since the beginning of the AIDS epidemic, many of the interventions designed for HIV-
positive persons were used in support groups or in structured group programs in which 
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the focus of the program and the outcomes of interest were improving mental health, 
social support, or coping rather than decreasing risk behavior.10-15  Some of these 
programs did measure changes in risk behaviors, and some have found that a focus on 
coping or mental health is related to decreased risk behaviors.16  After 1996, when new, 
more successful HIV medications began to be used, risk reduction interventions for HIV-
positive persons became a major focus of research and programmatic interest. More 
studies of HIV risk-reduction programs for HIV-positive persons have been conducted in 
the past few years, although the results are available for only three studies.   
 
All three studies that have evaluated group-level interventions designed to reduce HIV 
risk behaviors among HIV-infected persons have found that the participants receiving the 
intervention reduced their HIV risk behaviors more than the comparison group(s) on at 
least one measure of risk behavior.3, 4, 17  In one study, small groups of HIV-infected men 
and HIV-infected women attended a 5-session intervention based on social-cognitive 
theory or a 5-session health maintenance support group.3 The intervention condition 
focused on strategies for practicing safer sexual behaviors; developing coping skills; 
enhancing decision-making skills for disclosure of HIV status to families, friends, and 
sex partners; and developing skills to maintain safer sex. Those who received the 
intervention reported less unprotected intercourse and greater condom use 6 months after 
the intervention ended than did the participants in the comparison groups. 
 
In another study, participants were HIV-positive persons who inject drugs and who were 
entering a methadone maintenance program.4 For 6 months, participants received one of 
two interventions: 
1. Comparison intervention, which included daily methadone, weekly individual 
substance abuse counseling, case management, and a 6-session HIV risk-reduction 
intervention  
2. Harm-reduction intervention, which included everything in the comparison condition 
plus manual-guided group psychotherapy sessions two times a week.  
At follow-up, people assigned to the harm-reduction intervention reported lower 
addiction severity scores, and they were less likely to engage in high-risk sex- and drug-
related behaviors 
 
Finally, in the study by Rotheram-Borus and her colleagues, HIV-positive youth were 
provided with 1 or 2 different modules (Stay Healthy, a 12-session group, and Act Safe, 
an 11-session group).17 Those who participated in the first module had increased coping 
in various domains, while participants in the second module had fewer unprotected 
sexual acts, fewer sex partners, fewer HIV-negative sex partners, and less substance use.  
This intervention was tested prior to HAART and has now been updated and is named 
“CLEAR: Choosing Life: Empowerment, Action, Results Intervention for youth living 
with HIV.”  (The manuals for the updated intervention for youth and for other 
interventions by that research group are available online.  The website is included in the 
Resources section below.)  
 
Two of the three effective group interventions are targeted to particular HIV-positive 
populations (i.e., persons entering a methadone program4 or youth17). Agencies working 
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with these populations should review the intervention materials available and use these 
interventions with the identified populations when possible. Agencies working with a 
more general population of HIV-positive persons should consider adopting the 
intervention by Kalichman and his colleagues for persons more suited for a group-level 
intervention.3   
 
Two other studies highlight promising interventions for men with haemophilia and their 
partners and men being released from prison.18,19  In both studies, however, the research 
or evaluation design was inadequate to measure the effect on behavior change. Agencies 
working with men with haemophilia or men about to be released from prison should 
review these interventions and talk to the authors about more recent information they 
might have about these programs. 
 
Individual-Level Interventions for HIV-Positive Persons   
Individual-level interventions may be appropriate for persons for whom group-level 
interventions are inappropriate or are not effective in accomplishing reductions in risk 
behavior.  Studies that have evaluated the effectiveness of individual-level interventions 
have reported mixed results.   
 
The study with the most successful outcome focused on HIV-positive women and found 
that peer support and services, including a component that is similar to peer-based case 
management, were effective in reducing risk behavior.20 In this study, HIV-positive 
women were randomized to one of two 6-month interventions. The interventions included 
a comparison condition, which provided comprehensive reproductive health services 
including health education and counseling on relevant topics, or the enhanced condition, 
which included comprehensive reproductive health services plus peer advocate services. 
HIV-positive peer advocates worked with the women individually or in groups to share 
information on condom use with the primary and secondary partners. The peer advocate 
also provided information on contraceptive use. Optional support groups met weekly 
while individual sessions occurred on an as-needed basis. Three types of individual 
sessions were held: 
1. Warm-up encounters to help develop rapport  
2. Stage-of-change encounters in which peers counseled the participants on specific target             
behaviors using stage-appropriate messages 
3. Other encounters in which the peers addressed other urgent needs, such as housing or        
     child custody. This last type of encounter appears similar to peer case management. 
 
At follow-up, the researchers found that women who were in the enhanced intervention 
had improved consistency in condom use, perceived condoms as more advantageous, and 
increased their level of self-efficacy for condom use. The researchers cited four reasons 
for the intervention’s success:  
1. Use of HIV-positive peers, which, during formative research, the women said they 
preferred, 
2. Close collaboration with case managers and community referral agencies due to the 
high unmet needs of participants, 
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3. Tailoring of the behavior change message to address current motivations, intentions, 
and partner characteristics, and 
4. Reinforcement of intervention messages for women in primary care settings because 
most were receiving medical care. 
 
Two studies of individual-level interventions for HIV-positive persons found no 
differences in risk-reduction behaviors between the intervention group(s) and the 
comparison group.21, 22  In the study that found no differences in risk reduction between 
peer-based case management and usual care,22 the authors proposed that their findings 
may have been due to the brevity of contact between the peer case managers and the 
participants, or to the extensive services for HIV-positive persons available in the study 
city (San Francisco) which may have made it harder for their intervention to make a 
difference in the risk behavior of the participants.    
 
Prevention Case Management 
A more intensive intervention may be necessary to meet the specialized needs of HIV-
positive persons with multiple medical, social, and economic challenges.  Prevention case 
management (PCM) is an intensive intervention that combines individual HIV risk-
reduction with case management to provide intensive on-going support.23-24  The 
intervention is intended for persons having or likely to have difficulty initiating or 
sustaining practices to reduce or prevent HIV transmission.23      
 
As defined by CDC’s PCM Guidance, PCM consists of the following components: 
1. Identifying, recruiting into the program, and engaging clients with the greatest need 
2. Screening and assessment to determine a client’s risk behavior and psychosocial 
needs 
3. Developing a client-centered plan for reducing risk behaviors 
4. Conducting multiple sessions of HIV risk-reduction counseling to maintain 
preventive behaviors 
5. Coordinating services with follow-up regarding success of referrals and need for 
additional services including coordinating with other types of case managers such as 
Ryan White funded case managers, Medicaid case managers, or other case managers, 
if appropriate. 
6. Monitoring and reassessment of clients’ needs, risks, and progress 
7. Discharging from PCM upon attainment of risk-reduction goals 
 
PCM guidelines also indicate that the following are essential: 
1. Small client load (12–20 clients) to allow intensive case management  
2. Integrated services and coordination of community and other service providers 
3. Well-defined evaluation plan 
 
Objective 
The purpose of this document is to encourage and guide health departments and 
community-based organizations in providing specialized assistance through PCM to 
HIV-positive persons with multiple and complex HIV risk-reduction needs.  
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Procedures 
1. Identify potential clients and collaborate with community-based organizations 
(CBOs), health departments, sexually transmitted disease (STD) clinics, HIV clinics, 
hospitals, clients, and others to refer high-risk HIV-infected clients to PCM. The 
PCM approach is based on the premise that some people may not be able to give high 
priority to HIV prevention when faced with problems that they view as being more 
important or more immediate.  PCM should be reserved for persons willing to discuss 
intimate sexual and drug-use behaviors. Eligibility for PCM should be prioritized to 
include clients presenting with multiple risk factors, such as a recently acquired STD, 
multiple sex or needle-sharing partners in the past 3 months whose HIV status is 
unknown or negative, and psychosocial issues that impact these risk factors (e.g., 
mental illness, substance abuse, homelessness, and violence/coercion).  
2. Engage in PCM with HIV-infected persons who report high-risk behaviors for HIV 
transmission. Because the clients who need PCM have multiple risk factors, 
substantial resources may be needed to identify, engage, and recruit them.  
3. PCM should be conducted by professional counselors and social workers with 
experience working with high-risk clients (e.g., licensed social workers). Client case 
loads should remain small (12–20 per prevention case manager).  If a jurisdiction has 
ample case management resources, the prevention case manager may perform fewer 
case management tasks and more risk-reduction activities. In such a case, the case 
load may be slightly larger for the prevention case manager. 
4. Develop screening and assessment instruments customized to the target population, 
including some or all of the following topic areas:  health, adherence to treatment, 
incidence of STD, substance/alcohol use, history of incarceration, mental health, 
sexual history, social support, skills to reduce transmission, barriers to safer behavior, 
strengths and competencies, and demographic information.  Develop guidelines for 
data collection and performance evaluation measures. These data are crucial for 
determining referral and client needs and providing effective PCM. 
5. At the time of initial assessment, case managers must provide clients with a voluntary 
informed consent document to be signed that assures confidentiality for the activities 
related to PCM.  Communication with other providers or referral sources about a 
particular client requires obtaining written, informed consent from that client to allow 
for sharing relevant information.  All information about clients should be securely 
stored in locked cabinets, and this should be communicated to clients.  Providing 
these safeguards is one of the first steps to building a trusting relationship with PCM 
clients and engaging them in the process. 
6. Prevention case managers, in collaboration with individual clients, should develop a 
client-centered prevention plan with measurable behavioral outcomes for reducing 
high-risk behaviors and maintaining low-risk behaviors. Risk-reduction activities 
should include an individualized risk-reduction session and may be supplemented by 
counseling for couples or groups. Risk-reduction activities should be theory-based 
and tailored to a person’s life circumstances.  Clients must be provided education 
about the increased risk of HIV transmission associated with having other STDs.  In 
addition, clients must be provided with partner counseling and referral services 
(PCRS) so that partner may be confidentially notified of their potential exposure to 
HIV. 
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7. Prevention case managers should provide active coordination of and linking to 
supportive services such as medical services, psychological treatment, substance 
abuse treatment, STD treatment, various social services, and other HIV prevention 
services. Agreements should be established to ensure availability and access to key 
service referrals for the target population.  A standardized referral process should be 
developed including a referral tracking system,  
8. Prevention case managers should meet with clients regularly so that they can provide 
monitoring and reassessment of the clients’ needs, risks.  At regularly designated 
times the case manager and the client should revise the Prevention Plan and 
accompanying activities as appropriate. 
9. Prevention case managers should establish a time frame for discharge from PCM after 
the client meets his or her risk-reduction goals or if the client is no longer 
participating in the program.  
10. Incentives may be considered for use any time during PCM from engagement until 
discharge, if the jurisdiction and the funding source approve of their use.  Appropriate 
incentives may include transportation cards or tokens, vouchers for food or other 
necessities, or in some cases, cash.  The use of cash and non-cash incentives should 
not be excessive so as to be coercive.   
11. Prevention programs should provide a well-defined evaluation plan. 
 
Working with Partners and Integration into Existing Services 
1. Clients may be identified and referred to PCM through a variety of sources including 
HIV testing facilities, such as public clinics and primary care facilities. Agencies that 
currently serve HIV-infected persons in an integrated setting (e.g., a setting where 
numerous services related to HIV are available, such as medical and pharmacy 
services and psychosocial support resources) or CBOs that are closely linked to these 
services, in a way that makes them highly accessible, are most appropriate for PCM 
programs. Clients who are referred to PCM but are not eligible should be referred to 
other appropriate services. 
2. In some PCM settings, clients may already have a Ryan White or other case manager. 
The PCM Guidance provided two standards that should be followed in all 
jurisdictions: 
a) Explicit protocol in place for structuring the relationship with Ryan White CARE 
Act case management providers or other case management providers must be 
established and should detail how to transfer and/or share clients 
b) No duplication of Ryan White or other case management for persons living with 
HIV, but PCM may be integrated into these services.  
In practice this means that jurisdictions should work together to coordinate services 
between these two programs. Generally, Ryan White-funded case management is 
intended to ensure coordination and continuity of needed entitlements, medical care 
and treatment, housing, and other social services. They are allowed to discuss risk-
reduction behaviors with clients, but they often do not have the time or the training in 
behavioral theory to do so in an effective manner. PCM is first and foremost an HIV-
prevention activity to reduce the transmission of HIV infection. The integration of 
these two services is affected by the services available in the community and the 
eligibility requirements for the various programs.  
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Programmatic Considerations 
1. Risk reduction needs vary across persons and time. Agencies working with HIV-
infected clients should avoid a one-size-fits-all approach to helping clients reduce 
their risk, but they should focus their PCM efforts on those with the greatest 
prevention need (e.g., those who are most likely to transmit HIV to their sexual or 
drug using partners). 
2. Intervention science has not developed to the point where there is an easy formula to 
match clients to interventions. But given scarce resources, agencies should focus on 




In May 2000, the Kansas City Free Clinic, an AIDS service organization offering a broad 
range of services to HIV-positive persons, established a PCM program for high-risk HIV-
negative persons and newly diagnosed HIV-positive persons who were not already 
connected with the community’s system of care and support.  Clients are referred into 
PCM services through a variety of clinic programs including HIV counseling and testing, 
HIV primary care, Ryan White HIV-funded case management, and prevention education, 
as well as from a variety of providers in the community.  Once they are eligible, the 
prevention case manager initially meets weekly with participants and has telephone 
contact between visits as needed.  The content of a typical case management session 
includes the review of the risk-reduction plan, follow-up on community referrals, and 
utilization of behavior change techniques such as motivational interviewing. Disclosure 
of HIV status is addressed in the ongoing risk reduction counseling.  Incentives such as 
bus passes, movie passes, gift certificates, and safer sex supplies are utilized as funding 
permits.    
 
PCM is integrated into the clinic through staff training, development, joint client case 
conferencing, and client service delivery protocols.  The prevention case managers 
coordinate prevention services with the Ryan White-funded case managers, HIV primary 
care providers, and the peer-to-peer treatment adherence program.  Prevention case 
managers have completed training in HIV/AIDS/STD knowledge, prevention counseling, 
CDC PCM Guidance, and prevention with HIV-positive persons, and they receive 
ongoing training.  Case managers each have between 30-60 individuals on their caseloads 
each month, they meet with 40% of their clients monthly for risk reduction counseling 
services, and in each quarter, about 5 clients are discharged from PCM.  The clinic 
employs a variety of quality assurance and evaluation methods for the staff and the 
program.  For example, in December 2002, the PCM staff conducted a focus group with 
their HIV-positive clients, who were primarily MSM, to educate staff about the 
prevention needs of MSM and strengthen the clinic’s PCM program.  The staff found that 
clients needed: 1) more support and information on substance abuse, 2) flexible times to 
meet with PCM staff, and 3) more information about topics such as daily struggles, 
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Monitoring Implementation 
CDC grantees receiving HIV prevention funds will be required to routinely report the 
following indicators to monitor their HIV prevention interventions with persons living 
with HIV, including prevention case management programs. 
 
CDC’s HIV Prevention Program Performance Indicators*:  
1. Proportion of HIV infected persons who completed the intended number of 
sessions in PCM  (I.1) 
2. Proportion of the intended number of HIV infected individuals to be reached who 
were actually reached (H.2) 
3. The mean number of outreach contacts required to get one HIV infected person to 
access prevention case management services (H.3) 
4. Percentage of HIV infected persons who, after a specific period of participation in 
a prevention case management program, report a reduction in sexual or drug using 
risk behaviors or maintain protective behaviors with seronegative partners or with 
partners of unknown status (I.2) 
Other program measures: 
5. Number of persons receiving prevention interventions that are diagnosed with a 
new STDs, indicating transmission risk behavior 
7. Demographics of persons receiving prevention interventions and overall HIV-
infected persons in the community (e.g., race/ethnicity, gender, socioeconomic 
status) 
8. Collection of HIV transmission risk data in accordance with CTR Guidelines 
 
* The CDC Technical Assistance Guidelines for Health Department HIV Prevention 
Program Performance Indicators provides information on setting baseline, target, and 
indicator specification including appropriate data sources, calculations and reporting 
issues. Note: Performance indicators may have been modified to reflect specific 
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Prevention in Medical Care Settings 
 
Current Knowledge 
Despite significant advances in the treatment of HIV infection, the estimated number of 
annual new HIV infections in the United States has remained at 40,000 for nearly 10 years.1 
Historically, HIV prevention in this country has generally focused on persons who are not 
HIV-infected, to help them avoid becoming infected. However, further reduction of HIV 
transmission will require new strategies, including an increased emphasis on preventing 
transmission by HIV-infected persons aware of their status.2,3 This may be a highly cost-
effective strategy in that prevention is targeted directly to potential sources of new infections. 
After testing positive for HIV, many people reduce behaviors that may transmit HIV to 
others.4,5 However, recent studies suggest that such behavioral changes are not maintained by 
all HIV-infected persons and that some continue to engage in behaviors that place others at 
risk for HIV infection.6,7
 
Routine HIV prevention programs and support are needed to help HIV-infected persons 
reduce behavioral risks and maintain safer behavior in the years after the diagnosis of HIV 
infection. Studies have tested interventions in this population and have demonstrated 
significant reductions in risky sexual and drug-use behaviors. For example, in a study at 
public HIV clinics of HIV-infected persons who had multiple sex partners at baseline, the 
prevalence of unprotected anal and vaginal intercourse was reduced 38% after brief, ongoing 
prevention counseling from primary care providers.8 Successful risk-reduction interventions 
for HIV-infected persons have also been conducted in group settings.9 Further, interventions 
for HIV-infected persons who inject illicit drugs have reduced illicit drug use and unsafe sex 
in this population.10, 11 A number of studies have demonstrated the beneficial effect of 
substance abuse treatment, particularly methadone maintenance treatment, on HIV risk 
behaviors among injection drug users (IDUs).12 Taken as a whole, the findings strongly 
suggest that a concerted, sustained effort to provide prevention counseling and appropriate 
referral to services can greatly benefit HIV-infected persons and help them maintain safer 
behaviors that prevent others from becoming infected with HIV. However, recent studies 




The purpose of this document is to assist HIV medical providers, health departments, and 
community-based organizations (CBOs) to enhance HIV prevention services for HIV-
infected persons by 
• Increasing the number of positive persons who have information about transmission risks 
and regularly receive counseling about ways to reduce the risk of transmitting HIV to 
others 
• Increasing the number of sexually active HIV-infected persons who are screened and 
tested for sexually transmitted diseases (STDs) 
• Enhancing the capacity and ability to conduct effective prevention counseling and 
referral for services (e.g., social, mental health, drug treatment, partner notification) 
• Strengthening the linkages among health departments, CBOs, and providers of HIV care 
to facilitate the referral of HIV-infected persons to needed services 
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Procedures 
Steps for HIV care providers  
1. HIV prevention counseling should become a standard in the care for persons infected 
with HIV who continue to engage in behaviors that lead to HIV transmission. Providers 
of HIV care should assess the current level and characteristics of their prevention efforts, 
including allocation of resources, staffing, materials, and time devoted to this activity. 
The assessment should be used to guide planning and training needed to meet the diverse 
prevention needs of HIV-infected men and women. 
2. HIV clinics should display in waiting and exam rooms prevention posters and other 
printed materials (e.g., brochures describing partner counseling and referral services and 
other prevention behaviors) that convey the importance of safer sex and safer substance-
use behaviors. Prevention materials should emphasize the importance of abstinence, safer 
sex behaviors, and reducing or abstaining from drug use to protect partners as well as 
one’s own health. Examples of prevention messages and ways to reduce risk are 
presented in Attachment 1. 
3. HIV care programs should provide patients with written information (e.g., brochures or 
brief pamphlets) about:  
a) Behaviors that increase and behaviors that decrease transmission risks 
b) Role of STDs in increasing HIV transmission and the need to be tested and treated for 
STDs at the first sign or suspicion of infection 
c) Importance of disclosing one’s HIV infection status to sex partners 
d) Viral load and transmission risk emphasizing that having an undetectable or low viral 
load does not mean that one cannot transmit HIV 
e) Drug use and its potential role in increasing sexual risk behaviors 
4. At each visit, health care providers should ask patients about behaviors associated with 
HIV transmission using a straightforward, nonjudgmental approach. At the initial clinic 
visit, patients should be questioned about symptoms and screened for laboratory evidence 
of STDs. Decisions about subsequent testing should be guided by behavioral screening 
and the patient’s symptoms manifestations. See Attachments 2 and 3 for tests for 
detecting asymptomatic STDs. 
5. The primary care provider (e.g., physician, physician assistant, nurse practitioner) should 
conduct a 3-5 minute counseling session each time a patient is seen. Providers should 
have a one-page sheet for personal use that outlines the intervention process (see 
intervention schematic below) that can be referred to as a tool and reminder for delivering 
the intervention. Providers are encouraged to emphasize a partnership or team approach. 
Providers could say the following: “The health care providers here are dedicated to 
helping our patients stay as healthy as possible. We must work as a team to do this; this 
means that you and I make a commitment to do all we can to keep you well and stop the 
spread of this disease. My role is to give you expert medical care, support you in making 
choices about your care and answer your questions. But your health really depends most 
on your own actions and behaviors. The two of us have to work together as a team to 
keep you as healthy as possible.” 
6. The primary care provider should verbally state prevention messages to the patient (see 
Attachment 1) and initiate a discussion of behavioral goals. For some patients, the goal 
will be to continue to be abstinent, for other patients the goal will be to continue to 
practice safer sex. For other patients, the goal(s) will be to reduce risk behavior(s) (e.g., 
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always using a condom, reducing number of sex partners). The goals should be recorded 
in the patient’s medical chart on a form designed to track the prevention intervention. 
This form should include a place for the provider to indicate that counseling was given on 
a specific date.  
7. Prevention messages can be reinforced at subsequent visits by other care providers, social 
workers or health educators; patients may be more receptive to the messages if they are 
conveyed by more than one person. 
8. At the next visit, the provider should inquire about progress toward goals and again 
convey prevention messages orally to the patient. The provider should reinforce (i.e., 
praise) healthy behavior and, if needed, discuss new ways to overcome barriers. The 
provider and patient should reset goals for next visit.   
9. During a counseling session it may become apparent that a patient needs more intensive 
counseling or needs a referral to address a personal issue that cannot be handled by the 
medical provider (e.g., substance use, domestic violence, depression, needs for housing 
or shelter). Each provider should have on hand a list of referral resources (including 
addresses, telephone numbers, and names of contact persons) in the clinic, medical 
center, and community. In making a referral, the provider (or other clinic staff) should 
attempt to link a patient immediately by helping schedule an appointment before the 
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c) Contacting staff in local programs to facilitate other referrals. Referral guides and 
other information can usually be obtained from local and state health department 
HIV/AIDS prevention and care programs  
A brief summary for effective referral is attached in the Appendix. 
 
Steps for health departments and CBOs  
The following recommendations are offered to help refine and expand services for HIV-
infected persons in health departments and CBOs. Some of the preceding recommendations 
for HIV care providers are also applicable to health departments and CBOs, such displaying 
posters and providing printed materials to cue patients to the importance of safer sex (item 2 
above), providing risk-reduction information (item 3 above) and prevention messages 
(Attachment 1), and refining referral mechanisms (items 8, 9 above). 
1. Health departments in collaboration with the Health Resources and Services 
Administration’s (HRSA) AIDS Education and Training Centers (AETC) or the 
STD/HIV Prevention Training Centers funded by CDC should facilitate the training of, 
and support for, HIV primary care providers to conduct HIV prevention counseling with 
patients during routine medical examinations. 
2. Directors of HIV/AIDS prevention programs at health departments should establish or 
confirm already established working relationships with CBOs and with medical directors 
of public and private HIV clinics. These relationships should be formalized in a written 
agreement. Each party should have a working knowledge of the services provided by the 
other. This relationship will facilitate coordinated efforts to provide prevention services, 
referral mechanisms, and medical care to HIV-infected persons. It is important that health 
departments and CBOs strive to link HIV-infected persons to medical care if they are not 
already in care, and that providers of HIV care should strive to make prompt and 
appropriate referrals for prevention or social services that cannot be provided at the 
clinic. 
3. Health departments and CBOs should also provide an array of services for HIV-infected 
persons. Health departments and particularly CBOs should offer prevention case 
management (PCM), which includes client-centered prevention counseling to help people 
adopt and maintain risk-reduction behaviors and access needed medical, psychological, 
and social services. 14 Needs may include treatment for drug or alcohol abuse; mental 
health services; intervention for sexual or physical abuse (victim or perpetrator); housing 
or transportation; nutritional, financial, and legal matters; and insurance coverage. Health 
departments should have staff and procedures for conducting partner notification 
services. All HIV-infected persons seen at health departments and CBOs should receive 
information on ways to reduce HIV transmission and receive prevention messages 
(Attachment 1).  
 
Working with Partners and Integration into Existing Services 
1. Health departments and medical directors at HIV clinics should consult with HRSA and 
local HIV/STD Prevention Training Centers to arrange assistance for training clinic 
medical staff to assess transmission risk and do prevention counseling.  
2. HIV clinics, health departments, and CBOs should work with local community planning 
groups to design, implement, and evaluate interventions that address the local needs 
determined by the community planning group. 
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3. Successful referral should be confirmed by contacting the referred person and the agency 
to which the referral was made. This includes linking HIV-infected persons to prevention 




1. Staff at HIV clinics, health departments, and CBOs should meet within their respective 
settings to discuss ways to integrate prevention into their services for persons who are 
HIV positive. These services must be offered and advertised in a way that does not 
stigmatize persons who are HIV positive or single out any particular group as responsible 
for new infections. 
2. It is important that all interventions, including behavioral and STD screening, discussions 
of sexual and drug-use behaviors, and referrals, be conducted with cultural sensitivity.  
 
Vignette 
The Partnership for Health (PfH) intervention, conducted at six public HIV clinics in 
California, is an example of a successful behavioral intervention.8 The intervention was 
conducted mostly by primary care providers at the clinic after relatively brief training. The 
theme conveyed the importance of a patient-provider team approach in addressing the 
medical and behavioral dimensions of care to help HIV-infected patients stay as healthy as 
possible. The intervention included the following: (a) Printed information (brochure) 
introduced the partnership theme, stated messages emphasizing the importance of safer sex, 
and gave examples of specific risk-reducing behaviors. At later clinic visits, patients received 
flyers containing prevention information. (b) Posters in the clinic waiting room conveyed the 
PfH theme, and posters in each exam room emphasized a specific prevention message. (c) 
Brief (3-5 minutes) counseling was conducted by the primary care provider who stated the 
importance of the partnership, communicated prevention messages, and discussed behavioral 
goals with patients (e.g., risk reduction, maintaining safer behaviors). Results indicated that 
the intervention significantly reduced sexual risk behavior among patients whose profiles at 
baseline indicated risky behavior patterns. 
 
Monitoring Implementation 
CDC grantees receiving HIV prevention funds that work with HIV care providers to 
incorporate prevention in medical settings will be required to routinely report the following 
indicators to monitor implementation. 
 
CDC’s HIV Prevention Program Performance Indicators*:  
1. Percentage of the intended number of HIV infected individuals to be reached who 
were actually reached with a prevention message (H.2) 
2. Percentage of HIV infected persons who, after a specific period of participation in 
prevention counseling, report a reduction in sexual or drug using risk behaviors or 
maintain protective behaviors with seronegative partners or with partners of unknown 
status (I.2) 
Other program measures that will require collaboration with health care providers providing 
prevention in care settings: 
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3. Number of persons with HIV who are referred for further prevention services, 
including partner counseling and referral services (PCRS) and prevention 
interventions for persons living with HIV. 
4. Number of persons with HIV who use the prevention services to which they are 
referred 
5. Number of persons with HIV who have a new STD diagnosis in a specified period 
6. Collection of HIV transmission risk data in accordance with CTR Guidelines 
7. Brief surveys of providers in HIV clinics before and after training to demonstrate the 
extent to which providers feel more prepared to conduct prevention counseling with 
patients 
8. Brief surveys of patients at HIV clinics to assess the proportion that received 
prevention messages, how the messages are being received, the proportion that 
received prevention counseling, how prevention counseling is perceived, and whether 
changes in risk behavior are reported.    
 
* The CDC Technical Assistance Guidelines for Health Department HIV Prevention Program 
Performance Indicators provides information on setting baseline, target, and indicator 
specification including appropriate data sources, calculations and reporting issues. Note: 
Performance indicators may have been modified to reflect specific population or setting 
characteristics.   
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Attachment 1 – Prevention in Medical Care Settings 
 
Examples of Prevention Messages  
1. Unsafe sex may make it harder for you to keep yourself healthy 
2. Unsafe sex also exposes other people to HIV infection 
3. Unsafe sex may expose you to sexually transmitted diseases (STDs) (such as syphilis or 
gonorrhea) or strains of HIV that are not easily treated 
4. Not having sex will prevent any possibility of infecting another person 
5. Injecting illicit drugs or taking them orally puts your health at risk 
6. Sharing injection needles with others exposes other people to HIV infection and may 
expose you to diseases such as hepatitis 
 
7.   If you and a sex partner don’t use latex condoms or latex barriers while having sex 
 You do not show that your own health and the health of your partner come first 
 You are more likely to get STDs that may be difficult for us to treat 
 You may get other strains of HIV that may be difficult to treat 
 You make it harder for your medical provider to care for you 
 You may worry about infecting your partner and feel guilty after having sex  
 
8.  There are a variety of ways to reduce risks to yourself and a sex partner. Many people 
with HIV use one or more of the following strategies 
 Choose not to have sex at all 
 Choose safer behaviors, such as mutual masturbation 
 Choose to have sex with a partner who is HIV-infected and to use protection (a 
condom) with this partner 
 Choose less risky behaviors such as oral sex, and use latex barriers during oral sex 
 Choose to have anal or vaginal sex, but always use a condom to reduce the risk of 
transmission 
 Choose to limit the number of people with whom you have sex 
 Choose to stop using alcohol and other drugs because being under the influence of 
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Attachment 2 - Prevention in Medical Care Settings 
 
Examples of Laboratory Tests to Detect Asymptomatic Sexually Transmitted Diseases 
in Persons Who Are Asymptomatic 
 
These recommendations apply to persons without symptoms or signs of STDs. Patients with 
symptoms (e.g., urethral or vaginal discharge; dysuria; intermenstrual bleeding; genital or 
anal lesions; anal pruritus, burning, or discharge; and lower abdominal pain with or without 
fever) or known exposure should have appropriate diagnostic testing regardless of reported 
sexual behavior or other risk factors. 
 
First Visit  
For all patients   
• Test for syphilis: Nontreponemal serologic test, such as rapid plasma reagin (RPR) or 
Venereal Disease Research Laboratory (VDRL) test  
• Test for urogenital gonorrhea: urethral (men) or cervical (women) specimen for culture; 
or urethral/cervical specimen or first-catch urine nucleic acid amplification test (NAAT) 
for Neisseria gonorrhoeae 
• Test for urogenital chlamydial infection: urethral (men) cervical (women) specimen or 
first-catch urine (i.e., the first 10-30 cc of urine voided after initiating the stream should 
be used; men and women) specimen for NAAT for Chlamydia trachomatis
 
For women 
• Test for trichomoniasis: wet mount examination or culture of vaginal secretions for 
Trichomonas vaginalis 
• Test for urogenital chlamydia: cervical specimen for NAAT for Chlamydia trachomatis 
should be performed for all sexually active women 25 years of age or younger, and other 
women at increased risk, even if asymptomatic. 
 
For patients who report receptive anal sex 
• Test for rectal gonorrhea: anal swab culture for Neisseria gonorrhoeae 
• Test for rectal chlamydia: anal swab culture for Chlamydia trachomatis, if available 
 
For patients who report receptive oral sex 
• Test for pharyngeal gonococcal infection: culture for Neisseria gonorrhoeae
 
NOTE:  The yield of testing for N. gonorrhoeae and C. trachomatis is likely to vary, and 
screening for these pathogens should be based on consideration of patient's risk 
behaviors, local epidemiology of these infections, availability of tests (e.g., culture 
for C. trachomatis), and cost. 
 
Later Routine Visits 
• The tests listed above should be repeated periodically (i.e., at least annually) for all 
patients who are sexually active or who inject drugs. More frequent testing (e.g., every 3 
months or 6 months) may be indicated for asymptomatic persons at higher risk. The 
presence of any of the following may indicate the need for testing more than once a year: 
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• Multiple or anonymous sex partners 
• Past history of any STD 
• Identification of other behaviors associated with the transmission of HIV or other 
STDs 
• Sex or needle-sharing partner(s) with any of the above risks 
• Life changes that may lead to an increase in risky behaviors (e.g., dissolution of a 
relationship) 
• High prevalence of STDs in the area or in the patient population.   
 
NOTE:  Testing or vaccination for hepatitis, pneumococcal disease, influenza, and other 
infectious diseases (e.g., screening pregnant women for syphilis, gonorrhea, 
chlamydia, and hepatitis B surface antigen) should be incorporated into the routine 
care of HIV-infected persons as recommended elsewhere.15,16,17
NOTE:  Symptomatic and asymptomatic herpes simplex virus (HSV) infection, especially 
with HSV type 2, is prevalent among HIV-infected persons and may increase the 
risk of transmitting and acquiring HIV. Therefore, some experts recommend 
routine, type-specific serological testing for HSV-2. Patients with positive results 
should be informed of the increased risk of transmitting HIV and counseled 
regarding recognition of associated symptoms.17 Only tests for detection of HSV 
glycoprotein G are truly type-specific and suitable for HSV-2 serologic screening. 
NOTE:  Local and state health departments have reporting requirements for HIV and other 
STDs, which vary among states. Information on reporting requirements can be 
obtained from health departments. Clinicians need to be aware of and comply with 
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Attachment 3 - Prevention in Medical Care Settings 
 
Available Diagnostic Testing for Detection of Sexually Transmitted Diseases 
 
Diagnostic tests are listed in order of preference for recommendation, with most highly 
recommended test listed first. Alternative tests should be performed if specimen cannot be 
obtained or if preferred test is not available. 
 
Syphilis 
• Darkfield examination or direct fluorescent antibody (DFA) of exudate of lesion 
• Serum nontreponemal tests, rapid plasma reagin (RPR), or Venereal Disease Research 
Laboratory (VDRL) for screening followed by serum treponemal tests such as fluorescent 




• Microscopic examination of wet mount or culture of vaginal secretions 
 
Herpes 
• Viral culture of genital or other mucocutaneous ulcers  
 
Gonorrhea 
Female Genitourinary (GU) tract 
• Culture of endocervical swab specimen 
• Nucleic acid amplification tests (NAAT) of endocervical swab specimen 
• NAAT of urine 
Male GU tract 
• Culture of intraurethral swab 
• NAAT of intraurethral swab 
• NAAT of urine 
Rectum/pharynx medium specimen 
• Culture of rectal or pharyngeal swab specimen with selective  
 
Chlamydia 
• NAAT of endocervical swab specimen  
Female GU tract 
• NAAT of urine 
• Unamplified nucleic acid hybridization test, enzyme immunoassay, or direct fluorescent 
antibody test of endocervical swab specimen 
• Culture of endocervical swab specimen 
Male GU tract 
• NAAT of intraurethral swab specimen 
• NAAT of urine  
• Non-NAAT or culture of intraurethral swab specimen 
Rectum/pharynx 
• Culture of rectal or pharyngeal swab specimen 
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• Direct fluorescent antibody test performed on rectal or pharyngeal swab specimen) 
 
NOTE:  NAAT of urine is less sensitive than that of an endocervical or intraurethral swab 
specimen. Chlamydia trachomatis-major outer membrane protein (MOMP)-specific 
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Achieving Universal HIV Testing of Pregnant Women 
 
Current Knowledge  
Since the first pediatric case of HIV infection was documented in 1984, tremendous 
medical and public health achievements have been made in preventing mother-to-child 
transmission of HIV. A key step toward ensuring that the perinatal HIV interventions 
offered are effective is to make sure that care providers know the HIV status of the 
pregnant women in their care. When a woman is identified as HIV infected during 
pregnancy, antiretroviral and obstetrical interventions can reduce the risk of having an 
infected baby to ≤2%. When preventive anti-retroviral treatment is not initiated until 
labor or birth of the newborn, the risk of for transmission is 9% to 13%.1-3 Without 
intervention, the risk for transmission is approximately 25% in the United States.4
 
Maximal reduction of perinatal HIV transmission in the United States depends on 
ensuring  
• Pregnant women receive prenatal care 
• Routine HIV screening of all pregnant women  
• Recommended antiretroviral regimens are used during the prenatal, intrapartum and 
postpartum periods for HIV-infected women and their infants, as well as obstetrical 
interventions for women during labor and delivery  
• Routine screening of women during labor and delivery or of the newborn when the 
mother’s HIV status has not been determined previously5 
 
Approximately 6,000 to 7,000 HIV-infected women gave birth in the United States in 
2000, resulting in an estimated 280 to 370 HIV-infected infants. In about 40% of the 
perinatal transmissions, health care providers were unaware of the mother’s HIV status 
before delivery. Additionally, in the November 15, 2002, issue of the Morbidity and 
Mortality Weekly Report, CDC published information on the most recently available 
prenatal HIV testing rates for the United States and Canada.6  The report includes a 
comparison of the HIV prenatal testing rates associated with different testing approaches. 
In opt-out, pregnant women are notified that an HIV test will be included in the standard 
battery of prenatal tests and procedures and that they may decline testing. In the more 
commonly used opt-in approach, pregnant women are given pretest counseling and must 
specifically consent, usually in writing, to an HIV test. 
 
Among states using the opt-in approach and in which data were collected from medical 
records during 1998-1999, testing rates ranged from 25% to 69%. Population-based data 
from Canada showed testing rates in three opt-in provinces of 54% to 83%. In contrast, 
medical record data from Tennessee, which uses the opt-out approach, revealed a testing 
rate of 85%. Data from Canadian provinces using opt-out approaches showed a 98% 
testing rate in Alberta and a 94% testing rate in Newfoundland and Labrador. At the 
University of Alabama’s 8 prenatal clinics, HIV testing rates rose from 75% to 88% after 
the opt-out approach was implemented.7
 
In an April 22, 2003 Dear Colleague letter to health departments, community-based 
organizations, and health care providers, CDC recommended that clinicians routinely 
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screen all pregnant women for HIV infection, using an opt-out approach, and that 
jurisdictions with statutory barriers to such routine prenatal screening consider revising 
them.8  For women whose HIV status is unknown when labor begins, CDC recommended 
routine rapid testing.9 CDC also encouraged clinicians to test any newborn for HIV 
whose mother’s HIV status is unknown.  
 
Objectives 
The purpose of this document is to provide guidance for state health departments to 
achieve 
• Universal routine prenatal HIV testing in order to minimize perinatal HIV 
transmission in the United States 
• Routine rapid HIV testing during labor and delivery for women whose HIV status is 
still unknown 
• Rapid HIV testing post partum for women of unknown HIV status or their neonates, 
when rapid testing at labor and delivery is not possible or been previously declined 
• Appropriate antiretroviral treatment and comprehensive follow-up care for HIV-
infected pregnant women and their infants 
 
Procedures  
During prenatal care 
1.   Health departments in collaboration with the AIDS Education and Training Centers 
(AETC) of the Health Resources and Services Administration’s (HRSA), medical 
organizations, and other partners, should facilitate the training of prenatal care 
providers in use of the opt-out approach, including documenting in a woman’s 
medical chart her HIV test results or that she declined testing. 
2.  Training should include the following key elements of the opt-out approach: 
a)  At the first prenatal visit, women should be given information, which can be 
written (such as a brochure or pamphlet) or shown in a video, about perinatal HIV 
transmission, testing, and prevention. 
b)  Women should be told that HIV testing will be included in the standard battery of 
prenatal tests and procedures. This information may be included in a consent form 
that women sign for all prenatal care and services. Specific procedures regarding 
consent will depend on state and local laws, regulations, and policies. 
c)  Women should be told that they have the right to decline testing. 
d)  HIV test results or the refusal to be tested should be documented in the woman’s 
medical chart. 
3. Health departments should distribute materials, which are being or have been 
developed by the American College of Obstetricians and Gynecologists (ACOG), 
including a fact sheet on HIV testing for providers, an information sheet for women 
on HIV and other prenatal tests, and forms for documenting HIV test results or 
decline of testing.   
4.  Health departments should encourage prenatal care providers who work in areas of 
high HIV prevalence to rescreen women for HIV during the third trimester.  
5.  For pregnant women who test positive for HIV, health departments should facilitate 
access to appropriate obstetric, medical, and social services for prevention, care, and 
treatment.  
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During labor and delivery 
Health departments should work with AETCs, medical organizations and other partners 
to provide training to hospital staffs on procedures for offering rapid testing during labor 
and delivery to pregnant women whose HIV status is unknown. Training should 
emphasize the need to document test results or refusals. The following are additional key 
points: 
1. Women in labor whose HIV status is unknown should be informed that rapid HIV 
testing will be done routinely to help protect her baby’s health unless she declines 
testing. 
2. Women should be informed that a negative rapid test result means that she is not HIV 
infected; a preliminary positive rapid test result means that she probably is HIV 
infected. 
3. If  a woman tests positive, she should be informed that medicines can be given to her 
during labor and to her newborn based on the preliminary test result to reduce the 
chance that the baby will become HIV infected. 
4. Confirmatory testing will need to be done if she has a positive rapid HIV test result. 
 
After birth 
Health departments should work with medical organizations and other partners to train 
hospital staff to screen the mother or the infant or both with a rapid HIV test as soon as 
possible if the mother’s HIV status remains unknown. Some states mandate newborn 
screening in this circumstance.  
 
Working with Partners and Integration into Existing Services 
1. State AIDS directors should arrange training in the opt-out approach and in rapid 
testing with  
• State and local medical organizations 
• Maternal and child health (MCH) programs 
• AIDS Education and Training Centers  
• Hospitals offering obstetrical services 
• Other venues such as family planning clinics and drug treatment centers serving 
pregnant women.  
They should ensure that training is provided in prenatal clinics funded by MCH 
programs. 
2. Working with ACOG and other partners, CDC has developed a model protocol for 
implementing rapid HIV testing in labor and delivery settings. The protocol should be 
disseminated to providers of obstetric services.  
 
Programmatic Considerations 
1. Implementing the opt-out approach into HIV screening of pregnant women may 
require changes in state laws to streamline pretest counseling and consent 
requirements and documentation of test results or decline of testing.  
2. State health departments should provide information about the expected public health 
benefits of the opt-out approach to local representatives of national health care 
provider organizations, community groups that focus on maternal and child health 
issues, and state and local government officials.  
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Vignette 
In 1995, the state of Texas passed a law to permit the opt-out approach to prenatal HIV 
testing. Prenatal care providers in Texas distribute to pregnant women brochures obtained 
from the state health department describing prenatal tests, including those for HIV. Most 
providers obtain a general written consent for the standard battery of prenatal tests, which 
includes a test for HIV. Decline of the HIV test must be documented in the medical 
record.  
 
Monitoring Implementation  
CDC grantees receiving HIV prevention funds will be required to routinely report the 
following indicators to monitor their HIV testing of pregnant women. 
 
CDC’s HIV Prevention Program Performance Indicators*:  
1. Proportion of women who receive an HIV test during pregnancy (D.1) 
2. Proportion of HIV-infected pregnant women who receive appropriate 
interventions to prevent perinatal transmission (D.2) 
3. Proportion of HIV-infected pregnant women whose infants are perinatally 
infected (D.3)  
Other program measures: 
4. Statewide perinatal testing rates, possibly using PRAMS data (see Resources for 
the PRAMS website) 
5. Hospital specific perinatal testing rates  
6. States with low prevalence of HIV among women of childbearing age or who 
have low cumulative numbers of perinatal HIV infection, and who adopt the chart 
review method to obtain this indicator, may choose to sample only among 
hospital(s) with the largest proportion of deliveries in the state 
7. Description of state laws related to perinatal HIV testing, including prenatal HIV 
testing and documentation, testing at labor and delivery, testing of the newborn 
and the use of rapid HIV testing.  
8. Description of state efforts to monitor perinatal HIV testing rates. 
9. Description of state efforts to promote routine prenatal HIV testing, including, for 
example: 
a) Number and location of provider trainings. 
b) Number and occupation of participants attending provider trainings 
c) Topics covered during training (e.g., the number, type, and destination of 
materials distributed)  
 
* The CDC Technical Assistance Guidelines for Health Department HIV Prevention 
Program Performance Indicators provides information on setting baseline, target, and 
indicator specification including appropriate data sources, calculations and reporting 
issues. Note: Performance indicators may have been modified to reflect specific 
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Appendix 
 
Guidelines for Counseling and Referral for Persons with Newly Identified 
HIV Infection 
 
This appendix summarizes key points for counseling and referring to services persons 
with newly diagnosed HIV infection, as outlined in the Revised Guidelines for HIV 
Counseling, Testing, and Referral (CDC. MMWR 2001;50(No. RR-19):1-54.).  Please 




Basic information and support 
• Ensure that the client receives and understands the meaning of the test result. 
• Provide psychological support and make referral for additional psychological support 
if indicated. 
• Ensure that the client knows where and how to obtain further information and 
services. 
 
Medical assessment and care 
• Provide, or make referral for, medical evaluation, care, and treatment (including 
sexually transmitted disease [STD] screening and care, screening and treatment or 
vaccination for viral hepatitis, and reproductive health services). 
 
Prevention 
• Advise client to refrain from donating blood, plasma, or organs. 
• Ensure that the client has sufficient accurate information about how HIV is 
transmitted and how transmission can be prevented. 
• Explicitly point out and explain misconceptions regarding HIV transmission risk 
associated with specific sexual behaviors or the sharing of drug-use equipment. 
• For sexually active clients, address strategies for preventing other STDs or 
bloodborne infections (e.g., gonorrhea, syphilis, hepatitis B virus, hepatitis C virus). 
• Provide, or make referral for, HIV prevention counseling that focuses on the client’s 
personal circumstances and risk and helps the client set and reach explicit behavior-
change goals to reduce the chance of transmitting HIV. 
• Assess need for, and provide, or make referral for, other HIV prevention services 
(e.g., individual or group prevention counseling, prevention case management). 
• Provide, or make referral for, partner counseling and referral services, in accordance 
with all applicable laws and regulations. 
 
Special issues for pregnant women 
• Provide information regarding the risk for perinatal HIV transmission, ways to reduce 
this risk, and the prognosis for infants who become infected. 
• Provide, or make referral for, specialty care from providers who are knowledgeable 
about perinatal HIV prevention. 
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• Provide, or make referral for, nondirective counseling regarding all reproductive 
options. 
 
Other support needs 
• Assess need for, and provide, or make referral for, other support services (e.g., drug 
or alcohol prevention and treatment; mental health services; legal services; assistance 
with housing, food, employment, transportation, and child care; and domestic or 
partner violence services). 
 
Follow-up 
• Consider scheduling a follow-up appointment 3 to 6 months after diagnosis to assess 
whether clients were able to initiate medical care, minimize transmission risk to 
uninfected partners, and access other needed services (e.g., partner counseling and 
referral services). 
 
Strategies for making effective referrals 
• Consult with the client to identify essential factors that (a) are likely to influence the 
client’s ability to adopt or sustain behaviors to reduce risk for HIV transmission or (b) 
promote health and prevent disease progression. 
• Match service referrals to the client’s self-identified needs and priorities. 
• In consultation with the client, assess and address any factors that make completing 
the referral difficult (e.g., lack of transportation or child care, work schedule, cost). 
• Provide information necessary to access the referral service (e.g., contact name, 
eligibility requirements, location, hours of operation, telephone number). 
• Provide or arrange assistance when indicated (e.g., schedule the appointment, address 
transportation needs). 
• Obtain the client’s consent to share identifying information to help complete and 
verify the referral. 
• Document referrals made, the status of those referrals (i.e., whether the referral 
service was accessed), reasons referrals were not accessed, and the client’s 
satisfaction with the referrals.
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Glossary  
 
AIDS: Acquired immunodeficiency syndrome. AIDS can affect the immune and central 
nervous systems and can result in neurological problems, infections, or cancers. It is 
caused by human immunodeficiency virus (HIV). 
 
Anonymous: In anonymous testing, client identifying information is not linked to 
testing information, including the request for tests or test results. 
 
Antiretroviral therapy: Treatment with drugs designed to prevent HIV from 
replicating in HIV-infected persons. Highly active antiretroviral therapy (HAART) is an 
antiretroviral regimen that includes multiple classifications of antiretroviral drugs. 
 
Capacity building: Activities that strengthen the core competencies of an organization 
and contribute to its ability to develop and implement an effective HIV prevention 
intervention and sustain the infrastructure and resource base necessary to support and 
maintain the intervention.  
 
Client-centered HIV prevention counseling: An interactive risk-reduction 
counseling model usually conducted with HIV testing, in which the counselor helps the 
client identify and acknowledge personal HIV risk behaviors and commit to a single, 
achievable behavior change step that could reduce the client's HIV risk. 
 
Collaboration: Working with another person, organization, or group for mutual benefit 
by exchanging information, sharing resources, or enhancing the other’s capacity, often to 
achieve a common goal or purpose. 
 
Community Planning Group: The official HIV prevention planning body that 
follows the HIV Prevention Community Planning Guidance to develop a comprehensive 
HIV prevention plan for a project area. 
 
Confidentiality: Pertains to the disclosure of personal information in a relationship of 
trust and with the expectation that it will not be divulged to others in ways that are 
inconsistent with the original disclosure. Confidentiality must be maintained for persons 
who are recommended and/or who receive HIV counseling, testing, and referral (CTR) 
services. 
 
Confidential HIV test: An HIV test for which a record of the test and the test results 
are recorded in the client's chart. 
 
Confirmatory test: A highly specific test designed to confirm the results of an earlier 
(screening) test. For HIV testing, a Western blot or, less commonly, an 
immunofluorescence assay (IFA) is used as a confirmatory test. 
 
Culturally Appropriate: Conforming to a culture’s acceptable expressions and 
standards of behavior and thoughts. Interventions and educational materials are more 
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likely to be culturally appropriate when representatives of the intended target audience 
are involved in planning, developing, and pilot testing them.   
 
Demographics: The statistical characteristics of human populations such as age, race, 
ethnicity, sex, and size. 
 
Duty to Warn: A legal concept indicating that a health care provider who learns that an 
HIV-infected client is likely to transmit the virus to another identifiable person must take 
steps to warn that person; state laws determine what actually constitutes a "duty to warn." 
 
EIA: Enzyme immunoassay. Sometimes referred to as ELISA (see next definition). A 
commonly used screening test to detect antibodies to HIV. 
 
ELISA: Enzyme-linked immunosorbent assay. A type of EIA (see previous definition). 
A commonly used screening test to detect antibodies to HIV. 
 
Evaluation: A process for determining how well health systems, either public or 
private, deliver or improve services and for demonstrating the results of resource 
investments.  
 
Evidence-based: Behavioral, social, and structural interventions that are relevant to 
HIV risk reduction, have been tested using a methodologically rigorous design, and have 
been shown to be effective in a research setting.  These evidence- or science-based 
interventions have been evaluated using behavioral or health outcomes; have been 
compared to a control/comparison group(s) (or pre-post data without a comparison group 
if a policy study); had no apparent bias when assigning persons to intervention or control 
groups or were adjusted for any apparent assignment bias; and, produced significantly 
greater positive results when compared to the control/comparison group(s), while not 
producing negative results. 
 
Freestanding HIV test site: A site that provides only HIV services. Sometimes 
referred to as alternate test site or anonymous test site. Change term use definition 
 
Group-level interventions: Health education and risk-reduction counseling that shifts 
the delivery of service from the individual to groups of varying sizes.  Group-level 
interventions use peer and non-peer models involving a range of skills, information, 
education, and support. 
 
Guidance: Information to assist in efforts to conduct HIV prevention activities; guiding 
principles. 
 
Guidelines: A dictated set of activities; policies. 
 
HIV: Human immunodeficiency virus, which causes AIDS. Several types of HIV exist, 
with HIV-1 being the most common in the United States. 
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HIV test: More correctly referred to as an HIV antibody test, the HIV test is a laboratory 
procedure that detects antibodies to HIV, rather than the virus itself. 
 
HIV prevention counseling: An interactive process between client and counselor 
aimed at reducing risky sex and needle-sharing behaviors related to HIV acquisition (for 
HIV-uninfected clients) or transmission (for HIV-infected clients). See also client-
centered HIV prevention counseling. 
 
Incidence: In epidemiology, the number of new cases of infection or disease that occur 
in a defined population within a specified time. 
 
Individual-level interventions: Health education and risk-reduction counseling 
provided  for one individual at a time.  ILIs help clients make plans for behavior change 
and ongoing appraisals of their own behavior and include skills-building activities.  
These interventions also facilitate linkages to services in both clinic and community 
settings (for example, substance abuse treatment settings) in support of behaviors and 
practices that prevent transmission of HIV, and help clients make plans to obtain these 
services. 
 
Informed consent: The legally effective permission of a client or legally authorized 
representative (e.g., parent or legal guardian of a minor child) to undergo a medical test 
or procedure. 
 
Injection drug user: Someone who uses a needle to inject drugs into his or her body. 
 
Jurisdiction: An area or region that is the responsibility of a particular governmental 
agency. This term usually refers to an area where a state or local health department 
monitors HIV prevention activities. (For example, Jonestown is within the jurisdiction of 
the Jones County Health Department.) 
 
Oral fluid test: A test using oral mucosal transudate, a serous fluid. To differentiate this 
fluid from saliva, an absorbent material is left in the mouth for several minutes. In an 
HIV-infected person, oral mucosal transudate is likely to contain HIV antibodies. 
 
Outcome Monitoring: Efforts to track the progress of clients or a program based upon 
outcome measures set forth in program goals.  These measurements assess the effects of 
interventions on  client outcomes such as knowledge, attitudes, beliefs, and behavior.  
Monitoring allows the identification of changes that occurred, but the intervention may 
not have been responsible for the change. This would take a more rigorous approach (see 
Outcome evaluation). 
Outcome evaluation: Outcome evaluation involves the assessment of the immediate 
or direct effects of a program on the program participants; for example, the degree to 
which the program increased knowledge of HIV/AIDS, perceived risk of infection, 
and/or decreased intent of engaging in risk behaviors related to HIV transmission. 
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Outcome evaluation also assesses the extent to which a program attains its objectives 
related to intended short- and long-term change for a target population.  
Partner counseling and referral services (PCRS): A prevention activity that aims 
to a) provide services to HIV-infected persons and their sex and needle-sharing partners 
so they can reduce their risk for infection or, if already infected, can prevent transmission 
to others and b) help partners gain earlier access to individualized counseling, HIV 
testing, medical evaluation, treatment, and other prevention and support services. 
 
Perinatal HIV transmission: Transmission of HIV from the mother to the fetus or 
infant during pregnancy, delivery, or breast-feeding. 
 
Positive test: For HIV, a specimen sample that is reactive on an initial ELISA test, 
repeatedly reactive on a second ELISA run on the same specimen, and confirmed positive 
on Western blot or other supplemental test indicates that the client is infected. 
  
Preliminary Positive: For HIV, a specimen that is reactive on an initial EIA or rapid 
test. A preliminary HIV positive test result must be confirmed by a reactive test result 
using Western blot or another supplemental test indicating that the client is infected.  
 
Prevalence: The number or percentage of persons in a given population with a disease 
or condition at a given point in time. 
 
Prevention case management (PCM): A client-centered HIV prevention activity 
that promotes adoption of HIV risk-reduction behaviors by clients with multiple, complex 
problems and risk-reduction needs. PCM is a hybrid of HIV prevention counseling and 
traditional case management that provides intensive, on-going, individualized prevention 
counseling, support, and referral to other needed services. 
 
Prevention counseling: An interactive process between client and counselor aimed at 
reducing risky sex and needle-sharing behaviors related to HIV acquisition (for HIV 
uninfected clients) or transmission (for HIV-infected clients). See also client-centered 
HIV prevention counseling and HIV prevention counseling. 
 
Quality assurance: An ongoing process for ensuring that the CTR program effectively 
delivers a consistently high level of service to the clients. 
 
Rapid HIV test: A test to detect antibodies to HIV that can be collected and processed 
within a short interval of time (e.g., approximately 10-60 minutes). 
 
Referral: The process through which a client is connected with services to address 
prevention needs (medical, prevention, and psychosocial support). There are four types of 
referral: Provider Referral: The provider informs the partner and refers him or her to 
counseling, testing, and other support services; Patient or Client Referral: The HIV-
infected client takes full responsibility to inform his or her partners of their possible 
exposure to HIV and refers them to counseling, testing, and other support services; 
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Contract Referral: If the HIV-infected client is unable to inform a partner within an 
agreed-upon time (e.g., 3 days), the provider has the permission and information 
necessary to do so; Dual Referral:  The HIV-infected client and the provider inform the 
partner(s) together.  
 
Risk assessment: Risk assessment is a fundamental part of a client-centered HIV 
prevention counseling session in which the client is encouraged to identify, acknowledge, 
and discuss in detail his or her personal risk for acquiring or transmitting HIV. 
 
Risk factor or behavior: Behavior or other factor that places a person at risk for 
disease.  For example, drug use is a factor that increases risk of acquiring HIV infection; 
and factors such as sharing injection drug use equipment, unprotected anal or vaginal 
sexual contact, and commercial unprotected sex increase the risk of acquiring and 
transmitting HIV. 
 
Risk screening: A brief evaluation of HIV risk factors, both behavioral and clinical, 
used for decisions about who should be recommended HIV counseling and testing. Risk 
screening is different from risk assessment. 
 
Screening: Performing a test for all persons in a defined population, is a basic, effective 
public health tool used to identify an unrecognized condition so that treatment can be 
offered before symptoms develop. 
 
Sensitivity: The probability that a test will be positive when infection or condition is 
present. 
 
Seroconversion: Initial development of detectable antibodies specific to a particular 
antigen; the change of a serologic test result from negative to positive as a result of 
antibodies induced by the introduction of antigens or microorganisms into the host. 
 
Specificity: The probability that a test will be negative when the infection or condition 
is not present. 
 
Testing: Performing a test because of a person’s clinical symptoms or behavioral risk 
factors, has been the predominant paradigm for diagnosing HIV. 
 
Voluntary HIV testing: HIV testing that is offered free of coercion. With voluntary 
HIV testing, participants have the opportunity to accept or refuse HIV testing. 
 
Western blot: A laboratory test that detects specific antibodies to components of a 
virus. Chiefly used as a confirmatory test following repeatedly reactive EIA tests or rapid 
tests. 
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